

**Practice Improvement Program**  
**2021 - 2022 Program Guide**  
**Primary Care**

***Enrollment Deadline: July 16, 2021***  
***Guide Published: June 15, 2021***

**Primary Contacts:**

Claire Hankins, Program Manager, Population Health  
415-615-4496

## Acknowledgements

*We are grateful to the PIP Advisory Committee and Staff at the participating organizations for their insights contributing toward the publication of this guide. Thank you for your inspiring commitment to improving health care for San Francisco residents.*

## Table of Contents

- Practice Improvement Program ..... 1
- Section I: 2021 - 2022 Practice Improvement Program (PIP) Overview ..... 4
- Section II: PIP History ..... 5
- Section III: Summary of Key Changes for PIP 2021 - 2022 ..... 5
- Section IV: PIP 2021 - 2022 Reporting Rules and Timeline ..... 6
- Section V: 2021 - 2022 PIP Scoring Methodology and Payment Details ..... 8
- Section VI: 2021 - 2022 Clinical Quality Domain ..... 9
- Section VII: 2021 - 2022 PIP Resources ..... 12
- Section VIII: 2021 - 2022 Primary Care Measure Specifications ..... 12
- ~~CQ 01: Diabetes HbA1c Test~~ ..... 13
- CQ 02: Diabetes HbA1c <8 (Good Control) ..... 14
- ~~CQ 03: Diabetes Eye Exam~~ ..... 15
- CQ 04: Routine Cervical Cancer Screening ..... 17
- CQ 05: Routine Colorectal Cancer Screening ..... 18
- CQ 06: Breast Cancer Screening ..... 19
- ~~CQ 07: Smoking Cessation Intervention~~ ..... 20
- CQ 08: Controlling High Blood Pressure (Hypertension) ..... 22
- CQ 09: Adolescent Immunizations ..... 23
- CQ 10: Childhood Immunizations ..... 25
- CQ 11: Child and Adolescent Well-Care Visits ..... 27
- CQ 12: Chlamydia Screening ..... 28
- ~~CQ 13: Timely Access to Prenatal Care~~ ..... 29
- ~~CQ 14: Postpartum Care~~ ..... 30
- ~~CQ 15: Asthma Medication Ratio~~ ..... 31
- CQ 16: Well Child Visits in the First 15 Months of Life ..... 33
- CQ 17: Well Child Visits in Children 15-30 Months of Age ..... 34
- DQ 1: Provider Roster Updates ..... 35
- ~~PE 1: Third Next Available Appointment~~ ..... 38
- ~~PE 2: Office Visit Cycle Time~~ ..... 40
- ~~PE 3: Staff Satisfaction Improvement Strategies~~ ..... 42
- ~~PE 4: Improvement in Patient Experience of Primary Care Access~~ ..... 44
- ~~PE 5: Primary Care Access as Measured by Appointment Availability Survey Compliance~~ ..... 47
- ~~PE 6: Improvement in Specialty Access~~ ..... 49
- SI 1: Depression Screening and Follow-up ..... 51
- SI 2: Follow-Up Visit After Hospital Discharge ..... 53
- SI 3: Opioid Safety ..... 55
- ~~SI 4: Providers Open to New Members~~ ..... 59
- SI 5: Percent of Members with a Primary Care Visit ..... 61
- ~~SI 6: Palliative Care~~ ..... 63
- Section VIII: Appendix ..... 65

## Section I: 2021 - 2022 Practice Improvement Program (PIP) Overview

<b>Primary Objectives</b>	<ul style="list-style-type: none"> <li>• Aligned with the Quadruple Aim:             <ol style="list-style-type: none"> <li>1. Improving patient experience</li> <li>2. Improving population health</li> <li>3. Reducing the per capita cost of health care</li> <li>4. Improving staff satisfaction</li> </ol> </li> <li>• Financial incentives to reward improvement efforts in the provider network</li> </ul>
<b>Eligibility Requirements</b>	<ul style="list-style-type: none"> <li>• Contracted clinic or medical group with SFHP</li> <li>• Assigned primary care medical home for 300+ SFHP members and/or HSF participants</li> </ul>
<b>Funding Sources</b>	<p>As approved by SFHP’s Governing Board:</p> <ul style="list-style-type: none"> <li>• 18.5% of Medi-Cal capitation payments</li> </ul>
<b>How Surplus Funds are Managed</b>	<ul style="list-style-type: none"> <li>• Participants’ unearned funds roll over from one quarter to the next for the duration of the year</li> <li>• At the end of the year, unused funds are reserved for training and technical assistance to improve performance in PIP-related measures</li> </ul>
<b>Measure Domains</b>	<p>There are four measure domains including:</p> <ul style="list-style-type: none"> <li>• Clinical Quality</li> <li>• Data Quality</li> <li>• Patient Experience</li> <li>• Systems Improvement</li> </ul>
<b>Measure Development Criteria</b>	<p>Measures that are appropriate for inclusion in PIP are measures that align with external health care measurement entities (e.g. HEDIS, PRIME, NCQA accreditation), SFHP organizational priorities, and/or PIP network priorities. Measures are not designed to incentivize providers to deny services to members. In order to make informed measure decisions, SFHP can request information from participants during the development phase, such as current performance, population (n) size, goal, measure source/rationale.</p> <p><b>All measures</b> should:</p> <ul style="list-style-type: none"> <li>• Affect a high volume of patients and/or a high-risk process.</li> <li>• Address an area that needs improvement. To that end, SFHP is committed to rewarding relative improvement as well as absolute performance.</li> <li>• Support SFHP priorities, including mandates from the Department of Health Care Services (DHCS), National Committee for Quality Assurance (NCQA), and the California Department of Managed Health Care (DMHC).</li> <li>• Have a proven methodology for measurement and data reporting prior to the start of the program year.</li> </ul>

	<ul style="list-style-type: none"> <li>Primary Care program only: Present improvement opportunities for multiple networks.</li> </ul> <p><b>Clinical Quality measures</b> should be:</p> <ul style="list-style-type: none"> <li>Quantitative</li> <li>Nationally recognized with an external comparator/benchmark</li> <li>Able to follow Priority Five scoring methodology</li> </ul>
--	--

## Section II: PIP History

In 2010, San Francisco Health Plan’s governing board approved the funding structure for the Practice Improvement Program (PIP), which launched in January 2011 with 26 participating provider organizations (clinics and medical groups). The long-term objective of PIP is to reward performance-based outcome measures, and has aimed to achieve this through the following stages:

- In the first two years of PIP in 2011-2012, participants were incentivized to build data and reporting capacities.
- In 2013, PIP introduced thresholds for clinical measures and began rewarding based on performance for the first time.
- In 2014, the Healthy San Francisco-funded initiative Strength in Numbers was fully integrated into PIP to streamline reporting requirements.
- In 2015, SFHP reduced the measure set to those most important and lowest performing measures.
- In 2016, Specialty Care access measures were added for medical groups because access remains the area for most opportunity with San Francisco’s Medi-Cal population.
- In 2017, new measures were added to the Clinical Quality domain to increase alignment with external entities **Error! Bookmark not defined.**
- In 2018, new measures were added to the Systems Improvement domain to support appropriate utilization of primary care visits and expansion of the palliative care Medi-Cal benefit.
- In 2019, the patient experience domain was assessed with the goal of strengthening the measure set to improve alignment with SFHP and participant improvement priorities, strengthen patient experience metrics (i.e. methodology and targets), and simplify reporting.

## Section III: Summary of Key Changes for PIP 2021 - 2022

*Changes in the PIP 2021 – 2022 measure set were brought to the PIP Advisory Committee and other stakeholders for input on relevancy, implementation, and general feedback.*

- 1) CQ Domain:
  - CQ 06: Breast Cancer Screening has been updated to reflect the pay-for-performance status. Please refer to section V for more information.
  - CQ 10: Childhood Immunizations has been updated to align with HEDIS measure Childhood Immunizations combo-10 (CIS), which is part of the California Managed Care Accountability Set. This measure will be pay-for-reporting and the first deliverable will be due Q1 2021.

- CQ 11: Well Child Visits for Children 3-6 Years of Age has been fully removed from PIP for the 2021 - 2022 program year.
  - CQ 11: Child and Adolescent Well Care Visits has replaced the retired measure. This measure will be pay-for-reporting and the first deliverable will be due Q1 2021.
  - CQ 16: Well Child Visits in the First 15 Months of Life has been added to the program in alignment with the California Managed Care Accountability Set. This measure will be pay-for-reporting and the first deliverable will be due Q1 2021.
  - CQ 17: Well Child Visits in Children 15-30 Months of Age has been added to the program in alignment with the California Managed Care Accountability Set. This measure will be pay-for-reporting and the first deliverable will be due Q1 2021.
- 2) SI Domain:
- SI 1: Depression Screening and Follow up has been updated to reflect the pay-for-performance status. Participants will now be scored on reaching internal PIP thresholds or relative improvement.

**Other updates to PIP program due to COVID-19:**

- 1) Reduced the total measure set from 28 measures to 16 measures. Please see specs for measures that have been temporarily removed from the program.
- 2) Temporarily modified the payment structure for participants who elect to participate in a Quality Improvement Project (QIP).
  - a. Allocate 50% of capitation withhold to traditional PIP payments.
  - b. Allocate 50% of capitation withhold to QIPs that aim to address identified health disparities.

## Section IV: PIP 2021 - 2022 Reporting Rules and Timeline

Reporting requirements and lookback periods vary based on the individual measure (see Section VII for detailed measure specifications). The four quarterly reporting deadlines fall on the last business day of the month following the quarter end date, as illustrated in the table below.

Quarter	Quarter End Date	Materials Due to SFHP	Lookback Period
Enrollment	June 30, 2021	Friday, July 16, 2021	For all measures, the quarter’s end date serves as the last day of the lookback period. Please see each measure’s specifications for the first day of the lookback period.
1	September 30, 2021	Friday, October 29, 2021	
2	December 31, 2021	Monday, January 31, 2022	
3	March 31, 2022	Friday, April 29, 2022	
4	June 30, 2022	Friday, July 29, 2022	

**Lookback period:** To determine the lookback period for each measure, please refer to the individual measure specification. For all measures, the final day of data to be included is the date listed under “Quarter End Date” above. The first day varies by measure based on lookback period. For example, measure SI 2 *Follow-Up Visit After Hospital Discharge* covers the three months of the quarter, whereas measure CQ 04 *Routine Cervical Cancer Screening* looks back either 3 or 5 years depending on the population.


### Late Submissions Acceptance Policy and Procedure

Late submissions will be accepted up to two weeks after each quarter’s deadline. Participants may arrange for an extension, if negotiated prior to the deadline. When an extension has been granted, points and payment will not be affected. When an extension has not been granted, the late submission will not be accepted and the participant will forfeit the associated points.

### Data Correction Policy

In order to more fully understand PIP’s impact and make informed decisions about measure development, SFHP relies on accurate data. In the event where the participant notices that incorrect data has been submitted, the participant should notify SFHP and submit their corrected data as soon as possible. If the data was originally submitted via the quantitative data template, SFHP may request that the quantitative data template be resubmitted.

If the corrected data results in a change in incentive earned, a reconciled payment may be made in some cases. The following diagram illustrates this process:



For example, if a participant earned and was paid out for 80% of funds in Quarter 2 and then submitted corrected Quarter 2 data that should have earned them 90% of funds, a reconciled payment would depend on their Quarter 3 performance. If they earn 100% of funds in Quarter 3, then all unearned funds from Quarter 2 were recouped by Quarter 3’s 100% payment. In this case, a reconciled payment is not necessary. However, if the participant only earned 90% in Quarter 3, a reconciled payment would be made based on how much they should have earned in Quarter 2.

Once a participant has been paid for the final quarter of the program year, reconciliation of funds is no longer possible due to program constraints. Regardless of ability to modify payment amounts, SFHP greatly appreciates corrected data whenever it is discovered to assist in program evaluation and decision making. For measures that use SFHP-produced data, the same process as above will be followed in the event that SFHP identifies a data accuracy issue.

### Data Validation Policy and Procedure

To best understand program efficacy and standardize reporting, SFHP is invested in promoting activities that support data validation. If issues arise, SFHP is invested in working with participants to validate and improve data collection. To validate data, SFHP engages in the following activities:

- Quantitative Data Validation

- With every quarterly submission, SFHP will compare the current quarter’s quantitative data to the prior quarter’s. If there is a difference that seems beyond what could be due to normal variation, SFHP will follow-up with the participant for more information.
- Clinical Quality Domain:
  - SFHP will compare self-reported data to SFHP-audited HEDIS data on an annual basis. Some variation is expected given the difference in denominator populations. Significant variation will be analyzed further in collaboration with participants.
- PE 1 Third Next Available Appointment and PE 2 Office Visit Cycle Time:
  - SFHP may audit the data collection process to ensure consistent methodology is being used.
  - In addition, SFHP will use grievance data as another mechanism for validation. As part of our normal grievance investigation process, we will conduct research to verify member experiences. Significant variation from PIP data will be analyzed further in collaboration with participants.
- During the course of the program year, SFHP may pursue additional validation activities as opportunities arise.

### Mid-Year Measure Change Policy

Mid-year measure changes are discouraged; however there are cases that merit a measure change mid-year. The following cases are used to evaluate a measure change request:

- When a measure no longer represents both participant and SFHP priorities.
- When a measure is dictated by external agencies and the agency removes their support for the measure.
- When the relevancy/validity of the measure is undermined due to substantive interim changes in medical evidence and/or widely accepted clinical practice guidelines including, but not limited to, USPTF guideline changes.

## Section V: 2021 - 2022 PIP Scoring Methodology and Payment Details

Incentive payments will be based on the percent of points achieved of the total points that a participant is eligible for in each quarter. Should a participant be exempt from a given measure (as described in the measures specifications), the total possible points allocated to that measure will not be included in the denominator when calculating the percent of total points received. Participants will receive a percent of the available incentive allocation based on the following algorithm:

- 90-100% of points = 100% of payment
- 80-89% of points = 90% of payment
- 70-79% of points = 80% of payment
- 60-69% of points = 70% of payment
- 50-59% of points = 60% of payment
- 40-49% of points= 50% of payment
- 30-39% of points= 40% of payment
- 20-29% of points = 30% of payment
- Less than 20% of points = no payment



The point allocation for each individual measure is determined based on the degree of alignment with overall program priorities and prioritization of the measure nationally. See individual measure specifications for details.

Measures are designed to be reasonably challenging. While SFHP wants to distribute the maximum funds possible, the primary goal is to drive improvement in patient care. Pairing high quality standards and a financial incentive is just one approach in achieving this goal. As has been the case each year, any funds not earned in one quarter will be rolled over into the next quarter. Funds not earned by the end of the program year are reserved for training and technical assistance to improve performance in PIP-related measures.

To acknowledge success even if the top thresholds are not met, points are available for some measures when relative improvement tiers are met, defined as:

$$\text{Relative Improvement} = (\text{Current Rate} - \text{Baseline Rate}) / (100 - \text{Baseline Rate})$$

Within 6-8 weeks after the quarterly deadline, participants will receive a scorecard indicating how payment was calculated. Participants will be given one week from the date they receive their quarterly scorecard to notify SFHP of any needed scoring corrections.

Payments will be disbursed quarterly via electronic funds transfer, within two weeks of the scorecard being sent. Participating organizations will receive their first PIP payment for Quarter 1 by December 2021, and their last payment for Quarter 4 by September 2022. All payments will be announced via email notification.

Timely submission of claim/encounter data is important for improving performance on quality measures, advocating for adequate rates from the state, and ensuring fair payments to providers. Participants will only be eligible for PIP incentive payments during quarters in which at least one encounter file is received each month in the correct HIPAA 837 file format. Failure to submit at least one data submission each month will result in disqualification from PIP payments for all domains for the relevant quarter. Those funds will NOT be rolled over into the next quarter. All measures that are scored with claims/encounter data require data to be in the correct HIPAA 837 file format. SFHP provides a data clearinghouse (OfficeAlly) for submitters who do not have this ability; please contact the PIP Team for more information on this option.

#### Measure Exemptions


Each measure has certain requirements for exemptions, see the specifications for details. Exemptions are determined once for the program year upon enrollment and communicated to participants via the annual measure grid. Thus, if a participant is determined to be exempt from a measure at the beginning of the year, they remain exempt from the measure for the remainder of the year. For those participants who are exempt from a measure, SFHP may have other resources for which to collaborate on improvement efforts. If interested, please contact the PIP team.

## Section VI: 2021 - 2022 Clinical Quality Domain

Due to its complexity, the following information is provided about the Clinical Quality Domain.

### **Clinical Quality Reporting Methodology**

The reporting methodology for the clinical quality domain is self-report only. Below is a summary schematic of the reporting options:



Participants that choose to self-report data on a quarterly basis have the option to either:

- Report on their entire clinic population if the vast majority of the population is represented in the participant’s electronic system (Registry, EHR, etc.), supporting payer-neutral population management, **OR**
- Report on their SFHP members only.
  - Participants where the proportion of SFHP members to their overall population is small (generally < 10%) are required to choose this option. **To request an exemption from this, please speak with SFHP prior to enrollment.**
- For either option:
  - Eligibility will be determined via the baseline submission process. Participants will be exempt from all measures where the self-reported denominator is less than 30.
  - How to account for patient-reported data:
    - Compliant: include patient-reported data when the following criteria are met:
      - Verified by receiving results/notes or speaking with staff at the other facility
      - Test date, result, and facility recorded in the medical record
    - Not compliant: patient-reported data not meeting the above criteria

PIP participants must indicate a reporting methodology upon enrollment for each measure (entire-population data vs. only SFHP member data) and maintain it for the entire program year. Inconsistency in method of reporting will create challenges in scoring and determining earned funds.

### **Clinical Quality Scoring**

Deliverable	Quarterly Scoring (Self-Report)
<b>For each of the Priority Five measures:</b>	
Achieving HEDIS 90 <sup>th</sup> percentile or 75 <sup>th</sup> internal PIP percentile or 15% or more relative improvement	1.25 points
Achieving HEDIS 75 <sup>th</sup> percentile or 60 <sup>th</sup> internal PIP percentile or 10-14% relative improvement	1.0 point
Achieving 5-9% relative improvement =	0.75 point
<b>For each of the non-Priority Five measures:</b>	
Self-reporting data quarterly	0.25 point
Maintaining performance relative to baseline*	0.25 point

\*Maintaining performance relative to baseline = Maintaining baseline is defined as either maintaining/attaining the top threshold (found on page 11) or greater than -5.0% relative improvement. For example, relative improvement of -4.0% will be awarded points whereas -5.0% will not be awarded points.

**Priority Five Measures Determination:** Each participant’s Priority Five measures will be re-set in 2021 to allow new, lower performing measures to be targeted for improvement. However, due to the condensed measure set, many participants will keep similar Priority Five measures. Measures eligible for Priority Five inclusion are all Clinical Quality Measures that are being scored on performance. To determine Priority Five inclusion, self-reported data from Q6 2019-20 through Q3 2020-21 will be used. Participants will be notified in June 2021 their Priority Five measures. As before, participants will be allowed to swap up to one measure of their choosing, as long as the new measure is not currently at the top percentile.

**Clinical Quality Thresholds**

For measures with NCQA HEDIS thresholds:

Measure	90 <sup>th</sup> percentile	75 <sup>th</sup> percentile
CQ01 Diabetes HbA1c Test	-	-
CQ02 Diabetes HbA1c <8	60.77	55.96
CQ03 Diabetes Eye Exam		-
CQ04 Cervical Cancer Screening	72.68	67.4
CQ06 Breast Cancer Screening	69.22	64.06
CQ08 Controlling High Blood Pressure	72.75	67.64
CQ09 Adolescent Immunizations	50.85	43.06
CQ10 Childhood Immunizations	52.07	44.77
CQ11 Child and Adolescent Well-Care Visits	77.08	72.99
CQ12 Chlamydia Screening	71.42	66.26
CQ13 Timely Access to Prenatal Care	-	-
CQ14 Postpartum Care	-	-
CQ15 Asthma Medication Ratio	-	-
CQ 16: Well Child Visits in the First 15 Months of Life	-	-
CQ 17: Well Child Visits for Children 15-30 Months of Age	-	-

*For measures without HEDIS Medicaid thresholds, a PIP network threshold will be used based on prior year’s PIP participant data:*

Measure	75 <sup>th</sup> percentile	60 <sup>th</sup> percentile
CQ05 Colorectal Cancer Screening	60.66	37.95
CQ07 Smoking Cessation Intervention	-	-

## Section VII: 2021 - 2022 PIP Resources

Based on the amount of feedback received over the past few years, SFHP has consolidated all resource information online: <http://www.sfhp.org/providers/practice-improvement-program-pip/>. This information has been removed from each individual measure specification.

## Section VIII: 2021 - 2022 Primary Care Measure Specifications

The rest of this document consists of the individual specifications for each of the 2021 - 2022 measures across all domains: clinical quality, patient experience, and systems improvement.

Please see *Appendix B: Measure Set by Participant-Type Grid* for details on the measures assigned by participant-type (i.e. Community Clinic, Clinic-Based RBO, IPA, or Academic Medical Center).

## ~~CQ 01: Diabetes HbA1c Test~~

2021 - 2022 Practice Improvement Program Measure Specification

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

### **ALL PARTICIPANTS**

#### **Changes from 2020**

No Changes.

#### **Measure Description**

Participants will receive points for improvement on the percentage of patients with diabetes (type 1 and type 2) in the eligible population who received an HbA1c test in the last 12 months.

$$\text{DM HbA1C Test} = \frac{\text{Numerator: Number of patients in denominator population who received at least one HbA1c test within the last 12 months}}{\text{Denominator: Number of active patients with diabetes ages 18-75 years old}}$$

#### **Measure Rationale**

With support from health care providers and others, people with diabetes can reduce their risk of serious complications by controlling their levels of blood glucose and blood pressure and by receiving other preventive screenings in a timely manner. Studies have shown that reducing A1c blood test results by 1 percentage point (e.g., from 8.0 percent to 7.0 percent) reduces the risk of microvascular complications (e.g. eye, kidney, and nerve diseases) by as much as 40 percent (AHRQ, National Quality Measures Clearinghouse, 2014). In addition, monitoring HbA1c levels is an important first step towards diabetes control with the potential to reduce health care costs associated to treatment for diabetic complications.

The Department of Health Care Services (DHCS) requires SFHP to report HbA1c testing as part of the annual HEDIS measure set. This measure is also part of the DHCS' auto-assignment program measure set. In the auto-assignment program, Medi-Cal Managed Care members are preferentially assigned to the health plan with the highest performance on each of six measures, of which HbA1c screening is one.

#### **Measure Source**

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA Accreditation, HEDIS measure CDC: Comprehensive Diabetes Care, EAS, SWP4P, PCMH 6: Performance Measurement and Quality Improvement, and NQF (#0057).

#### **Definitions & Exclusions**

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.

#### **Deliverables and Scoring**

Please reference Section VI for information on all Clinical Quality deliverable and scoring information.

## CQ 02: Diabetes HbA1c <8 (Good Control)

2021 - 2022 Practice Improvement Program Measure Specification

### ALL PARTICIPANTS

#### Changes from 2020

No Changes.

#### Measure Description

Participants will receive points for improvement on the percentage of patients with diabetes (type 1 and type 2) in the eligible population whose most recent HbA1c results in the last 12 months was lower than 8%.

$$\text{DM A1c<8} = \frac{\text{Numerator: Number of patients in denominator whose most recent HbA1c level is } < 8.0\% \text{ in the last 12 months}}{\text{Denominator: Number of active patients with diabetes ages 18-75 years old}}$$

#### Measure Rationale

With support from health care providers and others, people with diabetes can reduce their risk of serious complications by controlling their levels of blood glucose and blood pressure and by receiving other preventive screenings in a timely manner. Studies have shown that reducing A1c blood test results by 1 percentage point (e.g., from 8% to 7%) reduces the risk of microvascular complications (e.g. eye, kidney, and nerve diseases) by as much as 40 percent (AHRQ, National Quality Measures Clearinghouse, 2014). In addition, improvements in HbA1c control is associated to decreased morbidity and mortality from diabetes and, thus, can reduce health care costs associated to treatment of diabetic complications.

The Department of Health Care Services (DHCS) requires SFHP to report HbA1c control as part of the annual HEDIS measurement set.

#### Measure Source

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA accreditation<sup>1</sup>, HEDIS measure CDC: Comprehensive Diabetes Care, EAS, SWP4P, and NQF(#0575).

#### Definitions & Exclusions

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.

#### Deliverables and Scoring

Please reference Section VI for information on all Clinical Quality deliverable and scoring information.

<sup>1</sup> SFHP held accountable

## ~~CQ 03: Diabetes Eye Exam~~

2021 - 2022 Practice Improvement Program Measure Specification

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

### **ALL PARTICIPANTS**

#### **Changes from 2020**

No changes.

#### **Measure Description**

Participants will receive points for improvement on the percentage of patients with diabetes (type 1 and type 2) who received a retinal eye exam by an eye care professional in the last 12 months, OR a negative retinal or dilated eye exam (negative for retinopathy) by an eye care professional in the past 24 months OR has had a bilateral eye enucleation

$$\text{DM Eye Exam} = \frac{\text{Numerator: Number of patients in denominator population with retinal exam or dilated eye exam performed by an eye care professional in the past 12 months OR a negative retinal or dilated eye exam performed by an eye care professional in last 24 months OR has had a bilateral eye enucleation}}{\text{Denominator: Number of active patients with diabetes ages 18-75 years old}}$$

**Denominator:** Number of active patients with diabetes ages 18-75 years old

#### **Measure Rationale**

Diabetic retinopathy is the leading cause of adult blindness in the U.S., and can be prevented with timely diagnosis (CDC, 2013). As such, the Department of Health Care Services (DHCS) includes Diabetic Eye Screening as a performance measure for all Medi-Cal Health Plans and the percent of diabetics that received an eye screening is an NCQA HEDIS measure. Studies indicate that diabetes eye exams, like retinal exams, can reduce health complications from diabetes and reduce health care costs for treatment of diabetic complications. One study found that screening and treatment for eye disease in patients with type II diabetes generates annual savings of \$24.9 billion to the federal government (American Diabetes Association, 1994).

#### **Measure Source**

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA accreditation<sup>1</sup>, HEDIS measure CDC: Comprehensive Diabetes Care, EAS, SWP4P, and NQF(#0575).

#### **Definitions & Exclusions**

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.
- Blindness is **NOT** an exclusion for a diabetic eye exam because it is difficult to distinguish between individuals who are legally blind but require a retinal exam, and those who are completely blind and therefore do not require an exam.

## **Deliverables and Scoring**

Please reference Section VI for information on all Clinical Quality deliverable and scoring information.



# CQ 04: Routine Cervical Cancer Screening

2021 - 2022 Practice Improvement Program Measure Specification

## ALL PARTICIPANTS

### Changes from 2020

No Changes.

### Measure Description

Participants will receive points for improvement on the percentage of patients with cervixes 24–64 years of age who received one or more Pap tests in the last 3 years to screen for cervical cancer. Patients with cervixes ages 30-64 who received cytology/human papillomavirus (HPV) co-testing during the past 5 years can also be included in the numerator.

$$\text{Cervical Cancer Screening} = \frac{\text{Numerator: Number of patients with cervixes ages 24-64 who received one or more cervical cytology during the past 3 years OR patients with cervixes ages 30-64 who received cervical cytology and HPV co-testing during the past 5 years}}{\text{Denominator: Number of active patients with cervixes ages 24-64 years old}}$$

### Measure Rationale

Cervical cancer can be detected in its early stages by regular screening using a Pap (cervical cytology) test. A number of organizations, including the American College of Obstetricians and Gynecologists (ACOG), the American Medical Association (AMA), and the American Cancer Society (ACS), recommend Pap testing every one to three years for all patients with cervixes who have been sexually active or who are over 21 (ACOG, 2003; Hawkes et al., 1996; Saslow et al., 2002; AHRQ, National Quality Measures Clearinghouse, 2014). Meeting and exceeding targets for cervical cancer screenings may ensure patients receive life-saving, preventive care. As such, screenings can identify cancer early and reduce health care costs associated to cancer treatments for advanced illness.

The Department of Health Care Services (DHCS) requires SFHP to report Cervical Cancer Screening as part of the annual HEDIS report. This measure is also part of the DHCS auto-assignment program measure set. In the auto-assignment program, Medi-Cal Managed Care members are preferentially assigned to the health plan with the highest performance on each of six measures, which includes Cervical Cancer Screening.

### Measure Source

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA accreditation<sup>1</sup>, HEDIS measure CCS: Cervical Cancer Screening, EAS, SWP4P, UDS reporting, and NQF(#0032).

### Definitions & Exclusions

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Patients who had a hysterectomy with no residual cervix, cervical agenesis or acquired absence of cervix prior to the measurement period are excluded.
- Participants with <30 SFHP members in the eligible population are exempt from this measure.

### Deliverables and Scoring

Please reference Section VI for information on all Clinical Quality deliverable and scoring information.

# CQ 05: Routine Colorectal Cancer Screening

2021 - 2022 Practice Improvement Program Measure Specification

## *Clinic-Based RBO & Community Clinic*

### Changes from 2020

No Changes.

### Measure Description

Participants will receive points for improvement on the percentage of members 51–75 years of age screened for routine colorectal cancer during the eligible time period.

<b>Colorectal Cancer Screening</b>	<b>=</b>	<b>Numerator:</b>
		Number of patients in denominator population who received a FOBT or FIT test during the past year,
		<b>OR</b>
		Number of patients in denominator population who received a sigmoidoscopy during the past 5 years,
		<b>OR</b>
		Number of patients in denominator population who received a screening colonoscopy during the past 10 years
<hr/>		
		<b>Denominator:</b> Number of active patients ages 51 - 75 years old

### Measure Rationale

Colorectal cancer kills more Californians than any other cancer except for lung cancer, yet it is one of the most preventable cancers. Despite an effective screening test, racial and ethnic disparities exist in colorectal cancer rates. San Francisco’s citywide dashboard, Community Vital Signs, tracks this measure and it is also a national HEDIS measure reported in Medicare and commercial health plans (Anderson, 2013). The proportion of adults 50 years of age and older who report use of either a fecal occult blood test (FOBT) or a sigmoidoscopy or colonoscopy within recommended time intervals has not changed since 2008 (American Cancer Society, 2015). Meeting and exceeding targets for colorectal cancer screenings can ensure that patients receive life-saving, preventive care. As such, screenings can identify cancer early and reduce health care costs associated to cancer treatments for advanced illness.

### Measure Source

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA accreditation, UDS reporting, and NQF(#0034).

### Definitions & Exclusions

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.

### Deliverables and Scoring

Please reference Section VI for information on all Clinical Quality deliverable and scoring information.

## CQ 06: Breast Cancer Screening

2021 - 2022 Practice Improvement Program Measure Specification

### All Participants

#### Changes from 2020

Measure is now pay-for-performance. Please see the scoring page for more information.

#### Measure Description

Participants will receive points for the reporting of the percentage of members 50–74 years of age who had a mammogram to screen for breast cancer.

**Numerator:** Number of patients in denominator population who received a mammogram within the past 24 months

**Breast Cancer  
Screening =**

**Denominator:** Number of active patients ages 52 - 75 years old

#### Measure Rationale

Breast is the second most common cancer in for people with breast tissue, after skin cancer with 25,000 people being diagnosed each year in California.<sup>1</sup> Despite an effective screening test, the CDC reports that after skin cancer, breast cancer is the most common cause of death from cancer among Hispanic women and the second most common cause of death from cancer among white, black Asian/Pacific Islander, and American Indian / Alaska Native women.<sup>2</sup> The United States Preventive Services Task Force, the American Cancer Society, and many others have affirmed that mammography is an important tool to reduce breast cancer mortality and that the benefits of mammography increase with age.<sup>3</sup>

#### Measure Source

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA, DHCS Medi-Cal Accountability Set, UDS reporting proposed starting in 2020, and NQF(#2372).

#### Definitions & Exclusions

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.

#### Deliverables and Scoring

Please reference Section VI for information on all Clinical Quality deliverable and scoring information.

<sup>1</sup>Medical Board. (2016, January). Medical Board of California.

[https://www.mbc.ca.gov/Publications/Brochures/Breast\\_Cancer.aspx](https://www.mbc.ca.gov/Publications/Brochures/Breast_Cancer.aspx)

<sup>2</sup>Breast Cancer Statistics. (2019, May). <https://www.cdc.gov/cancer/breast/statistics/index.htm>

<sup>3</sup>Final Update Summary: Breast Cancer: Screening - US Preventive Services Task Force. (2016, January).

<https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-screening1?ds=1&s=mammography>

## CQ 07: Smoking Cessation Intervention

2021 - 2022 Practice Improvement Program Measure Specification

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

### Clinic-Based RBO & Community Clinic

#### Changes from 2020

No Changes.

#### Measure Description

Participants will receive points for documenting that a smoking cessation intervention took place within the last two years for all patients who have a documented history of tobacco use and have been seen for an outpatient visit during that time. Include current patients with 1 visit in the past 12 months, and at least 2 visits ever.

<b>Smoking Cessation Intervention</b>	=	<p><b>Numerator:</b> Number of patients in denominator population with a documented smoking cessation counseling intervention in the EHR or registry in the last 2 years</p> <hr/> <p><b>Denominator:</b> Number of active patients who are <i>(must meet all of the following)</i>: <b>a.</b> 18 years or older; <b>b.</b> Have a documented history of tobacco use in the past 2 years</p>
---------------------------------------	---	--

#### Measure Rationale

Smoking and tobacco use is the leading preventable cause of death in the United States, causing more than 430,700 deaths each year. Despite the known health risks, over 47 million Americans smoke or use tobacco. As a result, medical spending surveys estimate that 8.7% of all healthcare spending, or \$170 billion a year, is used to treat tobacco-related illnesses, and public programs like Medicare and Medicaid paid for most of these costs (Reuters, 2014).

Seventy percent of smokers are interested in stopping smoking completely; furthermore, smokers report that they would be more likely to stop smoking if a doctor advised them to quit. A number of clinical trials have demonstrated the effectiveness of clinical quit-smoking programs. Simply receiving brief advice to quit is associated with a 30% increase in the number of people who quit (AHRQ, National Quality Measures Clearinghouse, 2014). In addition, lower education levels are associated with higher rates of smoking. For example, 22% of adults whose highest level of education is a high school diploma smoke, compared to 9% of adults with an undergraduate degree, and 5.6% of adults with a graduate degree (American Cancer Society, 2015).

Smoking cessation interventions may prompt smokers to initiate a quit attempt, which may not have otherwise occurred without an intervention. Patients who stop smoking often experience various health benefits from quitting and as such, quitting can reduce health costs associated with tobacco-related illness and treatment.

### **Measure Source**

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA accreditation<sup>1</sup>, HEDIS measure MSC: Medical Assistance with Smoking and Tobacco Use Cessation, CAHPS, UDS reporting, and NQF(#0028).

### **Data Source/Resources**

- Self-reported quarterly by clinics.

### **Definitions & Exclusions**

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.

### **Deliverables and Scoring**

Please reference Section VI for information on all Clinical Quality deliverable and scoring information.

# CQ 08: Controlling High Blood Pressure (Hypertension)

2021 - 2022 Practice Improvement Program Measure Specification

## **ALL PARTICIPANTS**

### Changes from 2020

No changes.

### Measure Description

Participants will receive points for reporting on the percentage of patients diagnosed with hypertension where appropriate blood pressure (BP) control, for their risk group, was attained.

$$\begin{array}{l}
 \text{Controlling} \\
 \text{High Blood} \\
 \text{Pressure} \\
 <140/90
 \end{array}
 =
 \frac{\text{Numerator: Number of patients in the denominator population in which the most recent BP reading in an outpatient visit within the reporting period was } <140/90 \text{ mmHG.}}{\text{Denominator: Number of active patients with hypertension ages 18-85 years old}}$$

### Measure Rationale

High blood pressure increases the risk of heart disease and stroke, the two leading causes of death in the United States (CDC, 2012). Controlling blood pressure has been proven to lower morbidity and mortality (AHRQ, National Quality Measures Clearinghouse, 2013). Some studies also indicate that failure to achieve blood pressure targets contribute to avoidable costs associated with a number of cardiovascular events (James, et al., 2014). In addition, the Department of Health Care Services (DHCS) requires SFHP to report this measure as part of the annual HEDIS report and it is included in the auto-assignment program measure set. In the auto-assignment program, Medi-Cal Managed Care members are preferentially assigned to the health plan with the highest performance on select measures.

### Measure Source

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA accreditation<sup>1</sup>, HEDIS measure CBP: Controlling High Blood Pressure, EAS, PRIME, Meaningful Use, UDS reporting, and NQF(#0018).

### Definitions & Exclusions

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.

### Deliverables and Scoring

Please reference Section VI for information on all Clinical Quality deliverable and scoring information.

# CQ 09: Adolescent Immunizations

2021 - 2022 Practice Improvement Program Measure Specification

## ALL PARTICIPANTS

### Changes from 2020

No changes.

### Measure Description

Participants will receive points for reporting the rate of adolescents who had one dose of meningococcal vaccine, one (Tdap)/(Td) vaccine, and two HPV vaccines by their 13th birthday.

$$\begin{array}{l}
 \text{Adolescent Immunizations with HPV} = \frac{\text{Numerator: Number of patients in the denominator population who received one meningococcal vaccine on or between the member's 11th and 13th birthday, one (Tdap) or (Td) vaccine on or between the member's 10th and 13th birthday, and two HPV vaccines between the member's 9th and 13th birthday.}}{\text{Denominator: Number of active patients who turned 13 years old during the last year}}
 \end{array}$$

### Measure Rationale

Adolescent immunization rates have historically lagged behind early childhood immunization rates in the United States. Low immunization rates among adolescents have the potential to cause outbreaks of preventable diseases and establish reservoirs of disease in adolescents that can affect other vulnerable populations including infants, the elderly, and individuals with chronic conditions. Meningococcal and (Tdap)/(Td) vaccines prevent illness and related outbreaks. In addition, the HPV vaccine is effective in preventing many types of cancers for people of all genders. Immunization research suggests disease prevention associated to immunizations saves hundreds of lost school days and work days, and millions of dollars associated with preventable illnesses (AHRQ, National Quality Measures Clearinghouse, 2014). As such, adolescent immunizations can save health care costs associated with preventable illnesses.

In addition to the assessment of missed immunizations, SFHP is also taking steps to evaluate the immunization rate of new vaccines that are targeted specifically to adolescents. This measure follows the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) guidelines for immunizations (AHRQ, National Quality Measures Clearinghouse, 2014).

The Department of Health Care Services (DHCS) requires SFHP to report this as part of the annual HEDIS report.

### Measure Source

Inclusion of this measure is supported by alignment with external healthcare measurement entities, including NCQA accreditation<sup>1</sup>, the HEDIS measure specification for Immunizations for Adolescents – Combo 2, and EAS.

### Definitions & Exclusions

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.
- Adolescents who had a contraindication for a specific vaccine are exempt from this measure.

### **Deliverables and Scoring**

Please reference Section VI for information on all Clinical Quality deliverable and scoring information.

### **Resources**

For guidance on how to treat patients who have already started the HPV vaccine with respect to the change in vaccine dosing guidelines, please see slide 34:

<https://www.cdc.gov/vaccines/ed/ciinc/downloads/2016-10-26/recommendations-hpv-2-doses-2016.pdf>



# CQ 10: Childhood Immunizations

2021 - 2022 Practice Improvement Program Measure Specification

## ALL PARTICIPANTS

### Changes from 2020

Added hepatitis A, rotavirus, and influenza vaccines to numerator.

### Measure Description

Participants will receive points for improvement on the rate of children who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV); one measles, mumps and rubella (MMR); three haemophilus influenza type B (HiB); three hepatitis B (HepB); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A; two or three dose rotavirus; and two influenza vaccines by their second birthday.

$$\begin{aligned}
 \text{Childhood Immunizations} &= \frac{\text{Numerator: Number of patients in the denominator population who received all of the following vaccines by their second birthday:}}{\text{Denominator: Number of active patients who turned 2 years old during the last year}}
 \end{aligned}$$

- four diphtheria, tetanus and acellular pertussis (DTaP);
- three polio (IPV);
- one measles, mumps and rubella (MMR);
- three haemophilus influenza type B (HiB);
- three hepatitis B (HepB),
- one chicken pox (VZV)
- four pneumococcal conjugate (PCV)
- one hepatitis A (HepA)
- two two-dose or three three-dose rotavirus (RV); and
- two influenza

### Measure Rationale

Childhood immunizations help prevent serious illnesses such as polio, tetanus, and hepatitis. Vaccines are a proven way to help a child stay healthy and avoid the potentially harmful effects of childhood diseases. Immunization research suggests disease prevention associated to immunizations saves hundreds of lost school days and work days, and millions of dollars associated with preventable illnesses (AHRQ, National Quality Measures Clearinghouse, 2014). As such, childhood immunizations can save health care costs associated with preventable illnesses.

This measure follows the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) guidelines for immunizations (Kroger et al., 2006). In addition, the Department of Health Care Services (DHCS) requires SFHP to report this as part of the annual HEDIS report and is included in the auto-assignment program measure set. In the auto-assignment program, Medi-Cal Managed Care members are preferentially assigned to the health plan with the highest performance on select measures.

### Measure Source

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA accreditation<sup>1</sup>, HEDIS measure CIS: Childhood Immunization Status—Combo 10, Meaningful Use, UDS reporting, and NQF(#0038).

### Definitions & Exclusions

- Please refer to the PIP webpage for numerator compliance and exclusion codes:  
<http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- For MMR, hepatitis, VZV and hepatitis A, count any of the following :
  - Evidence of the antigen or the combination vaccine
  - Documented history of the illness
  - A seropositive test result
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.
- Children who had a contraindication for a specific vaccine are exempt from this measure.

### Deliverables and Scoring

As a newly updated measure, participants will receive points for reporting only. Participants will be rewarded for improvement in the 2022-2023 program year.

# CQ 11: Child and Adolescent Well-Care Visits

2021 - 2022 Practice Improvement Program Measure Specification

## ALL PARTICIPANTS

### Measure Description

Participants will receive points on the rate of patients 3-21 years of age who had one or more Well-Care Visits with a PCP or an OB/GYN practitioner during the measurement year. The PCP does not have to be the practitioner assigned to the child.

$$\text{Well Care Visits} = \frac{\text{Numerator: Number of patients in the denominator population who had at least one well-care visit with a PCP or an OB/GYN practitioner during the past year.}}{\text{Denominator: Number of active patients 3-21 years old}}$$

### Measure Rationale

Assessing physical, emotional and social development is important at every stage of life, particularly with children and adolescents. Behaviors established during childhood or adolescence, such as eating habits and physical activity, often extend into adulthood. Well-care visits provide an opportunity for providers to influence health and development. They are a critical opportunity for screening and counseling.

The American Academy of Pediatrics (AAP) recommends annual well-care visits for 2 to 21-year-olds (AHRQ, National Quality Measures Clearinghouse, 2014).

### Measure Source

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities including HEDIS measure WCV: Child and Adolescent Well-Care Visits.

### Definitions & Exclusions

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.

### Deliverables and Scoring

As a first year measure, participants will receive points for reporting only. Participants will be rewarded for improvement in the 2021-2022 program year.

# CQ 12: Chlamydia Screening

2021 - 2022 Practice Improvement Program Measure Specification

## ALL PARTICIPANTS

### Changes from 2020

No changes.

### Measure Description

Participants will receive points for reporting the rate of sexually active patients able to become pregnant who had at least one chlamydia test in the last year.

$$\begin{array}{l}
 \text{Chlamydia Screening} = \frac{\text{Numerator: Number of patients in the denominator population with at least one test for chlamydia in the last year}}{\text{Denominator: Number of active patients who meet all of the following criteria:}} \\
 \begin{array}{l}
 \bullet \text{ are sexually active} \\
 \bullet \text{ have the ability to become pregnant} \\
 \bullet \text{ between the ages of 16-24 years old}
 \end{array}
 \end{array}$$

### Measure Rationale

Chlamydia is usually asymptomatic in people of all genders, and as a result infections often are undiagnosed. Approximately 3 million new infections are estimated to occur each year among sexually active people with the ability to become pregnant between the ages of 14-19. Chlamydial infections in patients with a cervix can cause cervicitis, which can cause Pelvic Inflammatory Disease (PID) if left untreated. The inflammatory and immune responses to PID can cause fallopian tube damage, scarring, and blockage which can result in long-term adverse outcomes of infertility, ectopic pregnancy, and chronic pelvic pain. Meeting and exceeding targets for chlamydia screenings supports health in patients with a cervix and can reduce health costs associated to complications from infection. This measure follows the Centers for Disease Control and Prevention (CDC) Division of STD Prevention’s Guidelines, (Centers for Disease Control and Prevention, 2014).

### Measure Source

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA accreditation<sup>1</sup> and EAS.

### Definitions & Exclusions

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.

### Deliverables and Scoring

Please reference Section VI for information on all Clinical Quality deliverable and scoring information.

## ~~CQ 13: Timely Access to Prenatal Care~~

~~2021 - 2022 Practice Improvement Program Measure Specification~~

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

### ***Clinic-Based RBO & IPA Participants only***

#### **Changes from 2020**

No changes.

#### **Measure Description**

Participants will receive points for reporting the rate of patients who received a prenatal care visit in the first trimester of their pregnancy or within 42 days of enrollment into Medi-Cal, whichever is later.

$$\begin{array}{l}
 \text{Timely} \\
 \text{Access to} \\
 \text{Prenatal} \\
 \text{Care}
 \end{array}
 =
 \frac{\text{Numerator: Number of patients in the denominator population who received a prenatal in the first trimester of their pregnancy or within 42 days of enrollment into Medi-Cal, whichever is later.}}{\text{Denominator: Number of active patients who had a live birth in the last year.}}$$

#### **Measure Rationale**

Prenatal care visits inform patients about the important steps they can take to ensure a safe pregnancy and protect their infant. As such, timely access to prenatal care can reduce complications from pregnancy and the associated health care costs.

#### **Measure Source**

Inclusion of this measure and PIP determination is supported by alignment with external healthcare measurement entities, including NCQA accreditation<sup>1</sup>, EAS, and PRIME.

#### **Definitions & Exclusions**

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.

#### **Deliverables and Scoring**

Please reference Section VI for information on all Clinical Quality deliverable and scoring information.

## CQ 14: Postpartum Care

2021 - 2022 Practice Improvement Program Measure Specification

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

### **Clinic-Based RBO & IPA Participants only**

#### **Changes from 2020**

No changes.

#### **Measure Description**

Participants will receive points for reporting the rate of patients that had a postpartum visit within 21-56 days OR 7-84 days\* after childbirth.

$$\text{Postpartum Care} = \frac{\text{Numerator: Number of patients in the denominator population who had a postpartum visit between 21-56 days OR 7-84 days after delivery.}}{\text{Denominator: Number of active patients who had a live birth in the last year.}}$$

#### **Measure Rationale**

Postpartum care provides important opportunities to assess the physical and psychosocial well-being of the parent, and for counseling on infant care. In addition, postpartum visits offer counseling on family planning, which can reduce the risk of unwanted pregnancies and save an estimated \$7 billion in Medicaid spending for the cost of unplanned births (Cleland et al., 2011).

\*NCQA has changed the 2020 postpartum measure specification from 21-56 days after delivery to 7-84 days. Participants will have the option to report on the old or new measure specification based on individual reporting needs.

#### **Measure Source**

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA accreditation<sup>1</sup>, EAS, and PRIME.

#### **Definitions & Exclusions**

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.

#### **Deliverables and Scoring**

Please reference Section VI for information on all Clinical Quality deliverable and scoring information.

## CQ 15: Asthma Medication Ratio

2021 - 2022 Practice Improvement Program Measure Specification

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

### **Clinic-Based RBO & IPA Participants only**

#### **Changes from 2020**

No changes.

#### **Measure Description**

Participants will receive points for reporting the rate of patients with persistent asthma who had a ratio of controller medication units to total asthma medication of 0.50 or greater.

**Numerator:** Number of patients in the denominator population who have a ratio of 0.5 or greater of controller asthma medication units to total asthma medications in the measurement year.

**Denominator:** Number of active patients between the ages 5-64 with persistent asthma as defined as one or more of the following in the past two years:

<b>Asthma Medication Ratio</b>	=	<ul style="list-style-type: none"> <li>• At least one ED visit with a primary diagnosis of asthma</li> <li>• At least one inpatient encounter with a primary diagnosis of asthma</li> <li>• At least four outpatient visits with a diagnosis of asthma <b>and</b> at least two asthma medication dispensing events</li> <li>• At least four asthma medication dispensing events                             <ul style="list-style-type: none"> <li>○ If the patient was only dispensed short acting medications (leukotriene modifier or antibody inhibitor) they should also have a diagnosis of asthma in any setting</li> </ul> </li> </ul>
--------------------------------	---	--

#### **Measure Rationale**

Asthma can be managed through the regular administration of asthma controller medications, which can control chronic symptoms and can prevent future exacerbation and progressive decline in lung function (or for children, reduced lung growth). The use of reliever or short acting medications will help ease acute symptoms but do not provide long-term asthma control and if used more than recommended, can cause long-term side effects. Asthma control strategies can reduce ED visits by as much as 68% and hospitalizations by as much as 85%, resulting in cost savings to inpatient care (CDC, 2015).

#### **Measure Source**

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA accreditation<sup>1</sup> and EAS.

#### **Definitions & Exclusions**

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- One controller medication unit is defined as an amount of medication lasting 30 days or less; one medication unit equals one inhaler canister, one injection, or a 30-day or less supply of an oral medication.

- Participants with < 30 SFHP members in the eligible population are exempt from this measure.
- Persistent asthma is defined as meeting at least one of the four denominator criteria.

**Deliverables and Scoring**

- Please reference Section VI for information on all Clinical Quality deliverable and scoring information.



# CQ 16: Well Child Visits in the First 15 Months of Life

2021-2022 Practice Improvement Program Measure Specification

## ALL PARTICIPANTS

### Measure Description

Participants will receive points for the reporting of the rate of children 15 months of age who had six or more Well Child Visits with a PCP during the measurement year. The PCP does not have to be the practitioner assigned to the child.

$$\text{Well Child Visits} = \frac{\text{Numerator: Number of patients in the denominator population who had at least six well-child visits before the child's 15-month birthday.}}{\text{Denominator: Number of active patients who turned 15 months old during the last year}}$$

### Measure Rationale

Well-child visits are important during the early months of a child's life to assess growth and development and identify and address any problems early. In addition, well-child visits can help to establish a strong relationship between parent(s) and pediatrician.

The American Academy of Pediatrics (AAP) recommends six well-child visits on or before a child's 15-month birthday (AHRQ, National Quality Measures Clearinghouse, 2014).

### Measure Source

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA accreditation, HEDIS measure W15: Well-Child Visits in the First 15 months of Life, MCAS, and NQF(#1392).

### Definitions & Exclusions

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.
- Well Child Visits should include evidence of monitoring physical, behavioral, and emotional development as well as checking immunization records at every visit and administering vaccines that are due.

### Deliverables and Scoring

As a first year measure, participants will receive points for reporting only. Participants will be rewarded for improvement in the 2021-2022 program year.

## CQ 17: Well Child Visits in Children 15-30 Months of Age

2021-2022 Practice Improvement Program Measure Specification

### **ALL PARTICIPANTS**

#### Measure Description

Participants will receive points for the reporting of the rate of children 30 months of age who had two or more Well Child Visits with a PCP during the measurement year. The PCP does not have to be the practitioner assigned to the child.

$$\text{Well Child Visits} = \frac{\text{Numerator: Number of patients in the denominator population who had at least two well-child visits between the child's 15-month plus 1 day and 30-month birthday.}}{\text{Denominator: Number of active patients who turned 30 months old during the last year}}$$

#### Measure Rationale

Well-child visits are important during the early months of a child's life to assess growth and development and identify and address any problems early. In addition, well-child visits can help to establish a strong relationship between parent(s) and pediatrician.

The American Academy of Pediatrics (AAP) recommends two well-child visits on or before a child's 30-month birthday (AHRQ, National Quality Measures Clearinghouse, 2014).

#### Measure Source

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including NCQA accreditation, HEDIS measure W30: Well-Child Visits in the First 30 months of Life, MCAS, and NQF(#1392).

#### Definitions & Exclusions

- Please refer to the PIP webpage for numerator compliance and exclusion codes: <http://www.sfhp.org/providers/practice-improvement-program-pip/>.
- Participants with < 30 SFHP members in the eligible population are exempt from this measure.
- Well Child Visits should include evidence of monitoring physical, behavioral, and emotional development as well as checking immunization records at every visit and administering vaccines that are due.

#### Deliverables and Scoring

As a first year measure, participants will receive points for reporting only. Participants will be rewarded for improvement in the 2021-2022 program year.

## DQ 1: Provider Roster Updates

2021 - 2022 Practice Improvement Program Measure Specification

### **IPA & ACADEMIC MEDICAL CENTER ONLY**

#### Changes from 2020

No changes.

#### Measure Description

Participants will receive points for reviewing SFHP provider data on a quarterly basis and providing new information when applicable. The process will be as follows:

1. *Within the first week after the quarter has ended:* SFHP will email SFHP-generated provider roster to designated PIP contact. Roster will include data regarding providers who were known to be active during the three months of the quarter. See Appendix A for an example.
2. *During the month after the quarter has ended:* the designated PIP contact will review the SFHP-generated provider roster. The roster will contain information for each provider known to be active at any point during the three months of the quarter. Contractors, courtesy staff, fellows, and residents are excluded. The following elements are *required* (unless stated otherwise) to be included about each provider:

- a) First and last name (legal with preferred in parenthesis)
- b) Medical degree
- c) Type of Practitioner (PCP or Specialist)
- d) Primary Specialty
- e) Secondary Specialties (*if applicable*)
- f) Language(s) spoken other than English (*if applicable*)<sup>2</sup>
- g) License number
- h) NPI
- i) Email address\*
- j) For NPs, PAs, CNMs only: Name of MD/DO Supervisor\* (*if applicable*)
- k) Site Name
- l) Language(s) spoken at site other than English (*if applicable*)
- m) Hours & Days Site is Open
- n) Date listed with SFHP
- o) Date terminated/left the organization\* (*if applicable*)
- p) Open to new members (Y/N)<sup>^</sup> (For PCPs only)
- q) Open to auto-assignment (Y/N)<sup>^</sup> (For PCPs only)

*\*This information is for SFHP internal use only.*

*<sup>^</sup>Not applicable to the SFHN.*

---

<sup>2</sup> SFHP providers are not required to speak English, however the vast majority do. Therefore in an effort to save time when reporting for this measure we will not require you to specify if providers speak English.

- *By the Quarter’s Due Date:*
  - When changes need to be made:
    - Return the SFHP-produced roster with changes noted in the first column
  - When no changes need to be made:
    - Indicate no changes in the first column
- Complete a Provider Roster Attestation verifying that all information has been reviewed and (if applicable) updates provided. Attestation and supporting information template (if applicable) should be uploaded via Wufoo.

**Measure Rationale**

Timely submission of updated provider rosters ensures that SFHP maintains key compliance objectives and accurate member assignments. SFHP does not routinely receive timely and accurate provider data from all clinics and medical groups. This has resulted in very poor scores on state audits; for example, a 2015 Department of Health Care Services audit found 88% of randomly selected SFHP provider data to have errors. Moreover, CA Senate Bill 137 requires all Knox-Keene-licensed health plans in California to collect much more robust provider data, effective 7/1/2016. The revised process for this measure will support SB137.

**Measure Source**

Inclusion of this measure is supported by alignment with external healthcare measurement entities, including the Department of Health Care Services (DHCS) Quality Measures for Encounter Data (QMED).

**Exclusions**

- The following providers should be excluded from the roster: contractors, courtesy staff, fellows, and residents.

**Data Source/Resources**

- Questions related to your provider roster can also be submitted to [provider.relations@sfhp.org](mailto:provider.relations@sfhp.org), or by calling (415) 547-7818 x7084.

**Deliverables and Scoring**

Deliverable	Due Dates	Scoring
<ul style="list-style-type: none"> <li>• If there are <b>no changes</b> that need to be made to the current quarter’s provider roster, please indicate so in the comments section of the roster.</li> <li>• If <b>changes do need to be made</b> to the current quarter’s provider roster, please submit the supporting information in one of the two approved ways. Deductions will be made in these cases:               <ul style="list-style-type: none"> <li>○ 0.10 point deduction (up to a maximum of 0.50 point) for each piece of missing information noted in Measure Description.</li> <li>○ 0.25 point deduction (up to a maximum of 1.0 point): Discrepancy between Medical Staff Office (MSO)/Profiles/Change Reports/Credentialing Packet and Provider</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Quarter 2</li> <li>• Quarter 4</li> </ul>	2.0 points

<p>Roster. Discrepancies that will affect scoring are:</p> <ul style="list-style-type: none"><li>• Providers in one source and not the other.</li><li>• Additions/terminations reported via PIP that should have been reported via entity's contractual method &gt; 1 month prior</li></ul>		
---	--	--

## ~~PE 1: Third Next Available Appointment~~

2021 - 2022 Practice Improvement Program Measure Specification

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

### **CLINIC-BASED RBO & COMMUNITY CLINIC ONLY**

#### **Changes from 2020**

No changes.

#### **Measure Description**

Participants will receive points for improving or meeting thresholds for Third Next Available Appointment (TNAA). Participants will submit data for the final five weeks each quarter, and SFHP will score performance based on median of the five pieces of data.

**How to calculate TNAA:** TNAA data should be collected once a week, at the same day and time of the week. Count the number of days between today and the third next available appointment for regular return visit for each provider/team. Then, take the median of all providers/teams and report that value for each of the final five full weeks of the quarter.

- Count calendar days (e.g. include weekends, holidays, and days off).
- Only count appointments saved for the appropriate appointment type (Do not count saved slots for urgent visits, new patient visits, or other appointment types that have special scheduling rules (since they are "blocked" on the schedule).
- The data can be collected manually or electronically. Manual collection means looking in the schedule book and counting from today to the day of the third available established patient follow-up appointment. Some electronic scheduling systems can be programmed to compute the number of days automatically.

#### **Measure Rationale**

As the industry standard for measuring access to appointments, the third next appointment best represents appointment access as it accounts for last minute cancellations. This measure is considered the overarching access measure, as it represents the impact of the combination of other access measures such as Show Rate and Cycle Time (National Quality Measures Clearinghouse, 2013). In addition, this measure supports operational efficiency of primary, preventative care. Timely access to preventive care can identify and treat health conditions early, potentially reducing health care costs from treatment due to health complications.

#### **Measure Source**

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including the Department of Managed Health Care regulations.

#### **Data Source**

- Self-reported by participant.
- CA Department of Managed Health Care guidelines:  
[http://www.dmhc.ca.gov/healthplans/gen/gen\\_timelyacc.aspx](http://www.dmhc.ca.gov/healthplans/gen/gen_timelyacc.aspx)

**Deliverables and Scoring**

<b>Deliverable</b>	<b>Due Dates</b>	<b># of Days Reduced</b>	<b>Threshold</b>	<b>Scoring</b>
Submit the median established patient follow-up visit TNAA for each of the final 5 full weeks of the reporting period, via the quantitative template. <b>Note:</b> SFHP will determine median of five pieces of data and use it to score performance.	<ul style="list-style-type: none"> <li>• Quarter 1</li> <li>• Quarter 2</li> <li>• Quarter 3</li> <li>• Quarter 4</li> </ul>	n/a	14 calendar days or less	2.0 points
		≥ 10 days	15-21 calendar days or less	1.5 points
		5-9 days	n/a	1.0 point

## ~~PE 2: Office Visit Cycle Time~~

2021 - 2022 Practice Improvement Program Measure Specification

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

**ACADEMIC MEDICAL CENTER, CLINIC-BASED RBO, COMMUNITY CLINIC ONLY**

### Changes from 2020

PIP Network performance thresholds updated.

### Measure Description

Participants will self-report primary care cycle time data for at least one site serving a large volume of SFHP members to receive points for either meeting a threshold or for the number of minutes reduced each quarter. All primary care providers at the site, including per diem and part-time providers, should be included in cycle time. Cycle time can be collected in one of the following ways:

- **Option A:** Electronically capture cycle time by using an electronic health record or practice management system.
- **Option B:** Manually collect cycle time by sampling a minimum of 15 patients per month on a consistent day and time (e.g. appointments on Mondays from 2:00 to 4:00 pm). If participants choose this option, we recommend utilizing the IHI Patient Cycle Tool found on the SFHP PIP webpage.

Each quarter, participants will submit the median cycle time for each month in the given quarter. SFHP will score performance based on the most recent month's median cycle time (Month 3). Please ensure the median in Month 3 on the quantitative data template represents the most recent month.

### Measure Rationale

Cycle time is an important indicator of patient satisfaction, clinic efficiency, and ultimately patient access. The goal is not to reduce value-added time spent with members of the care team, but to decrease the amount of time a patient spends waiting. Inclusion of this measure supports operational efficiency of primary preventive care. Timely access to preventive care can identify and treat health conditions early, potentially reducing health care costs from treatment due to health complications.

### Measure Source

Inclusion of this measure was informed by SFHP in conjunction with the PIP advisory committee.

### Definition

The office visit cycle time is defined as the amount of time that a patient spends at an office visit, beginning at the time the patient is checked in and ending at the time the patient is checked out (i.e. finished with their appointment).

### Data Source

- Self-reported.

### Deliverables and Scoring

Deliverable	Due Dates	# Minutes Reduced	PIP Network Threshold	Quarterly Scoring
-------------	-----------	-------------------	-----------------------	-------------------



Self-report the <u>median</u> cycle time for each month in the quarter, via the quantitative template.	<ul style="list-style-type: none"> <li>• <b>Quarter 1</b> (Data Collection Period: Jul, Aug, Sept)</li> <li>• <b>Quarter 2</b> (Data Collection Period: Oct, Nov, Dec)</li> <li>• <b>Quarter 3</b> (Data Collection Period: Jan, Feb, Mar)</li> <li>• <b>Quarter 4</b> (Data Collection Period: Apr, May, Jun)</li> </ul>	10 or more minutes reduced	<b>75<sup>th</sup> percentile</b> 63 minutes or less	1.0 point
		5-9 minutes reduced	<b>60<sup>th</sup> percentile</b> 64-68 minutes	0.5 point

## ~~PE 3: Staff Satisfaction Improvement Strategies~~

### 2021 - 2022 Practice Improvement Program Measure Specification

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

#### **Community Clinics, Clinic-Based RBOs, and Academic Medical Centers**

##### **Changes from 2020**

- No changes.

##### **Measure Description**

Participants will receive points for activities related to staff satisfaction. In order to guide these activities, a satisfaction survey of all staff will be implemented. In 2019, participants began to administer their own survey. Participants may choose to measure their Net Promoter Score, use the Gallup 12 staff satisfaction survey, or another method with SFHP approval. Technical assistance will be offered for participants seeking support with administering staff satisfaction surveys (including analysis and follow-through).

In order to ensure statistical significance, each survey administered must meet the following sample size thresholds in order to be eligible for the points awarded for performance in Quarter 4:

- Participants with 30-60 staff – 60% response rate
- Participants with 61-150 staff – 50% response rate
- Participants with more than 150 staff – 35% response rate

*Please note:* In order for scores to be comparable and participants to be eligible for full points, the same survey must be used for both the baseline and re-survey.

##### Tips for Increasing Staff Response Rate:

- Offer reward or recognition for completing survey (e.g. \$5 coffee gift card, staff lunch, for reaching a specific response rate)
- Regularly communicate the current response rate and goal.
- Reinforce and restate the changes that have been made due to prior staff satisfaction surveys.

##### **Measure Rationale**

Staff satisfaction has been shown to be directly related to patient experience (British Medical Journal, Szecsenyi et al, 2011). In addition to improved patient experience, other benefits to improving staff satisfaction include reduced turnover and associated reductions in training costs. Improved staff satisfaction is also linked to empowered staff who will work to continuously identify process improvements that result in health care cost-saving opportunities (Powell, 2011).

##### **Measure Source**

Inclusion of this measure is considered as reward for improvement, due to bias from varying patient populations.

##### **Exclusions**

- Participants with fewer than 30 staff are exempt from this measure.

**Deliverables and Due Dates**

Deliverables	Due Dates	Scoring
<p><b>Deliverable A:</b> Submit template with the following included:</p> <ul style="list-style-type: none"> <li>• Baseline score of a staff satisfaction survey               <ul style="list-style-type: none"> <li>○ If survey has multiple questions, only one score may be chosen. For participants using Net Promoter survey, chosen question must be “How likely are you to recommend organization as a place to work?”</li> </ul> </li> <li>• Survey type (Gallup, Net Promoter, etc.)</li> <li>• Survey date (completed October 1, 2018-January 15, 2018)</li> <li>• Survey question</li> <li>• Response rate (numerator/denominator)</li> <li>• 1-2 priority areas identified for improvement</li> </ul>	<p>Quarter 1</p>	<ul style="list-style-type: none"> <li>• 0.5 point for completed template, if required response rate met.</li> <li>• 0 point if required response rate not met.</li> </ul>
<p><b>Deliverable B:</b> Submit template with:</p> <ul style="list-style-type: none"> <li>• Report of improvement activities implemented</li> <li>• Survey type (must be same as <b>baseline</b>)</li> <li>• Survey date (completed August 1, 2016-October 15, 2016)</li> <li>• Survey question (must be same as baseline)</li> <li>• Response rate (numerator/denominator)</li> </ul>	<p>Quarter 3</p>	<p>1.0 point for completed template, if response rate met.</p>
<p><b>Deliverable C:</b> Improvement on staff satisfaction survey score, submitted via the Quantitative Data Template.</p> <ul style="list-style-type: none"> <li>○ Score must represent question chosen for baseline.</li> </ul>	<p>Quarter 3</p>	<p><i>If required response rate met:</i></p> <ul style="list-style-type: none"> <li>• 1.0 point for <math>\geq 4.0\%</math> relative improvement</li> <li>• 0.5point for 2.0% - 3.9% relative improvement</li> </ul> <p><i>If required response rate not met:</i></p> <p>0 point</p>

## ~~PE 4: Improvement in Patient Experience of Primary Care Access~~

### 2021 - 2022 Practice Improvement Program Measure Specification

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

#### **ALL PARTICIPANTS**

#### **Changes from 2020**

- No changes.

#### **Measure Description**

This measure uses information collected directly from patients to assess perceived access to care. Using a validated survey, participants will be scored on improvement from their baseline score rather than meeting a threshold score, due to bias from varying patient populations. Patient feedback can help providers capture the patient’s voice, gain more understanding of the patient population, and target specific improvement areas to improve the overall quality of health service delivery. As such, this measure can incentivize providers to understand more about patients’ needs and save future costs by identifying the right patient concerns and utilizing resources efficiently.

SFHP encourages the use of the CG-CAHPS survey tool as it meets the following criteria. Participants may choose to use a different survey tool as long as it meets the same criteria. To use this option, please contact PIP staff upon program enrollment. Survey tool must be comparable from baseline to re-measurement.

#### *Patient Experience Survey Tool Criteria*

	<b>Criteria</b>	<b>Rationale</b>
1.	Conducted and analyzed by <i>or</i> audited by third party	Supports consistent and unbiased survey methodology
2.	Surveyed population is a random sample of all Medi-Cal patients	Results can be generalized across the population
3.	Survey conducted at least twenty-four hours after visit concludes	Surveys conducted during or immediately after a visit can offer a limited view of the patient’s full experience, including follow-up services needed post visit
4.	Tool has been validated	Validation ensures that the tool is reliable; meaning, that it yields results that reflect patient perception of the health care system
5.	Includes access-related questions	Access to care represents the biggest opportunity for improvement for San Francisco’s Medi-Cal population, as it is the lowest ranking area on member surveys
6.	Sampling methodology ensures that each question obtains at least thirty responses	Results can be considered statistically meaningful

Participants will also receive points for collecting and analyzing qualitative data from patients, as well as developing and implementing a plan to improve baseline performance. Qualitative data collection must

come from at least 10 patients belonging to your clinic/group. Options include open-ended survey questions, focus groups, or key informant interviews.

**Measure Rationale**

Patient Experience with access is largely connected to clinical outcomes (Annals of Family Medicine, Llanwarne, et al, 2013). Historically this has been the lowest scoring composite for SFHP Medi-Cal members, falling below the 25th percentile for Health Plan CAHPS. CAHPS and equivalent surveys are rigorously developed to represent patients’ top healthcare experience factors and are validated to ensure that results represent patients’ true feelings. This measure supports participants in assessing and improving patient access using input directly from patients. Timely access to preventive care can identify and treat health conditions early, potentially reducing health care costs from treatment due to health complications.

**Measure Source**

Inclusion of this measure is supported by alignment with external healthcare measurement entities, including the PCMH 1: Patient-Centered Access guidelines, and is considered as reward for improvement, due to bias from varying patient populations.

**Definitions**

**CG-CAHPS:** The Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG-CAHPS) survey is a standardized tool to measure patients' perception of care provided by providers and teams in an office setting. The survey evaluates ease of access to care, provider communication with patients, and courtesy and helpfulness of office staff.

**Data Source**

- CG-CAHPS survey; please see Appendix C for full list of composite questions.
  - Other survey may be substituted if it meets the criteria outlined on the prior page and is approved by SFHP upon enrollment.

**Exclusions**

- Participants with less than 1,500 SFHP members are optionally exempt.

**Deliverables and Scoring**

Deliverables	Due Dates	Scoring
<p><b>Deliverable A:</b> Submit template with:</p> <ul style="list-style-type: none"> <li>• CG-CAHPS or equivalent baseline data</li> <li>• A description of the qualitative data collection methodology (sampling methodology, questions asked, and number of patients participating)</li> <li>• An analysis of themes found in qualitative data</li> <li>• Plan to improve results, based on qualitative data</li> </ul>	Quarter 2	<b>2.0 points</b> for completed template
<p><b>Deliverable B:</b> Submit template with:</p>	Quarter 4	<b>1.5 point</b> for completed template

<ul style="list-style-type: none"> <li>• Report of improvement activities implemented</li> <li>• Re-measurement data collection methodology</li> </ul>		
<p><b>Deliverable C:</b> Submit re-measurement score for CG-CAHPS or equivalent survey on Quantitative Data Template.</p>	<p>Quarter 4</p>	<p><b>Access to Care Composite ONLY:</b>  <b>2.0 points</b> for achieving:                  CG-CAHPS 90th percentile (90.9%)*                  or                  ≥3% absolute improvement</p> <p><b>1.0 point</b> for achieving:                  CG-CAHPS 60th percentile (88.7%)*                  or                  2-2.99% absolute improvement</p> <p><b>0.0 points</b> for &lt;2% absolute improvement</p>
<p><b>Deliverable D:</b> Submit all other composite scores for CG-CAHPS or equivalent survey on Quantitative Data Template.</p>	<p>Quarter 4</p>	<p><b>Customer Service and Provider Communication Composites:</b>  <b>0.5 point</b> for reporting results</p>
<p>*Press-Ganey medical group percentile scores (State of California); 7/1/2018-9/30/2018</p>		

## ~~PE 5: Primary Care Access as Measured by Appointment Availability Survey Compliance~~

### 2021 - 2022 Practice Improvement Program Measure Specification

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

#### **ACADEMIC MEDICAL CENTER & IPA ONLY**

#### **Changes from 2020**

No changes.

#### **Measure Description**

This measure uses information collected directly from providers to assess access to care. Health Plans are required to monitor appointment availability for all providers. Using the California Department of Managed Health Care (DMHC) Provider Appointment Availability Survey, participants will be scored on their overall compliance rate. The survey addresses a variety of access measures, including access to routine primary care, urgent primary care, routine specialty care, urgent specialty care, non-physician mental health, psychiatry, prenatal care, and ancillary care. For the purposes of this measure, scoring will include access to routine primary care and urgent primary care.

<b>DMHC Timely Access Regulations for Primary Care</b>	
Non-Urgent Primary Care Appointments	Within 10 business days of patient request
Urgent Primary Care Appointments	Within 48 hours of patient request

To implement the survey, SFHP will collaborate with the Industry Collaborative Effort (ICE), a group of health plans that collaborate to decrease the administrative cost of measurement and decrease the burden on providers. SFHP will submit a contact list of randomly selected providers to ICE. ICE will administer the survey via phone through a qualified survey vendor.

Provider compliance with appointment availability can be met by two ways:

1. Meeting standards for appointment regulations (listed above) on their own
2. Meeting standards for appointment regulations via another available provider in the same location

Each participant's score will represent a combination of non-urgent and urgent compliance rates.

$$\begin{array}{l}
 \text{Primary Care} \\
 \text{Appointment} \\
 \text{Availability}
 \end{array}
 = \frac{\text{Numerator: Total number of primary care providers in compliance with DMHC Appointment Availability standards listed above (must be compliant in both categories)}}{\text{Denominator: Total number of primary care providers that respond to the Appointment Availability Survey}}$$

#### **Measure Rationale**

The Timely Access to Non-Emergency Health Care Services Regulation (Timely Access Regulation) requires health plans to meet timeliness standards for provision of health care services, including wait time standards for appointments, as well as for customer service and triage (Knox-Keene Health Care Service Plan Act of 1975; California Code of Regulations, title 281; Bill SP 964). The Provider

Appointment Availability Survey is one component of the report submitted each March to DMHC. This measure supports participants in assessing patient access as well as operational efficiency of primary preventive care. Timely access to preventive care has can identify and treat health conditions early, potentially reducing health care costs from treatment due to health complications.

**Measure Source**

Inclusion of this measure and PIP benchmark determination was informed by the SFHP compliance department.

**Data Source**

- No submission due from PIP Participants.
- DMHC Provider Appointment Availability Survey for Primary Care (administered in the summer/fall)

**Deliverables and Scoring**

<b>Deliverable</b>	<b>Due Date</b>	<b>Scoring</b>
Participate in provider appointment availability survey (via phone, online, or fax)	Quarter 4. No submission due from participants.	<b>8.0 points</b> for achieving a 80% compliance rate



## PE 6: Improvement in Specialty Access

### 2021 - 2022 Practice Improvement Program Measure Specification

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

#### **CLINIC-BASED RBO & IPA ONLY**

#### **Changes from 2020**

No changes.

#### **Measure Description**

This measure uses information collected directly from members to assess perceived access to specialty care.

##### **Deliverable A**

- Participants will be awarded points for improving their score on the specialty care question relative to their baseline. SFHP recommends participants use the same specialty access question as the 2019 deliverable.

##### **Deliverable B**

- Participants will be awarded points for collecting and analyzing qualitative data from patients, as well as developing a plan to improve baseline performance. Qualitative data collection must come from at least 10 patients belonging to the participant's organization. Options include open-ended survey questions, focus groups, or key informant interviews.

#### **Measure Rationale**

Patient Experience with access is largely connected to clinical outcomes (Annals of Family Medicine, Llanwarne, et al, 2013). SFHP Medi-Cal members consistently report challenges with access, including access to specialty care. This measure supports participants in assessing member access using input directly from members. In addition, by assessing member experience and perception of access, this measure supports operational efficiency of preventive care. Improvements to timely access to preventive care can identify and treat health conditions early, potentially reducing health care costs from treatment due to health complications.

#### **Measure Source**

Inclusion of this measure supported by alignment with external healthcare measurement entities, including NQF #0006, and is considered as reward for improvement, due to bias from varying patient populations.

#### **Data Source**

- Quantitative and qualitative data collected directly from patients by the participant or participant's vendor.

**Deliverables and Scoring**

Deliverable	Due Date	Scoring
<p><b>Deliverable A:</b> Submit specialist access score via quantitative template</p>	<p>Quarter 2</p>	<p><b>1.0</b> Points for achieving 3% or more absolute improvement over baseline score on the specialist access question  <b>1.0</b> Points for achieving 2-2.9% absolute improvement  <b>0.0</b> Point for achieving &lt;2% absolute improvement</p>
<p><b>Deliverable B:</b> Submit template with:</p> <ul style="list-style-type: none"> <li>• An explanation of the methodology used to analyze the data</li> <li>• An analysis of themes found in qualitative data</li> <li>• Plan to improve results, based on qualitative data</li> </ul>	<p>Quarter 4</p>	<p><b>1.0</b> Point for reporting an analysis of themes found in qualitative data.  <b>1.0</b> Point for a reporting a plan to improve results, based on qualitative data.</p>

# SI 1: Depression Screening and Follow-up

## 2021 - 2022 Practice Improvement Program Measure Specification

### **ALL PARTICIPANTS**

#### Changes from 2020

Updated scoring methodology to reflect pay-for-performance.

#### Measure Description

Participants will receive points for reporting the rate of patients receiving depression screening and a follow-up to a positive screening, as described below.

$$\begin{array}{l}
 \text{Depression Screening Rate} = \frac{\text{Numerator: Total number of patients with a negative depression screening AND total number of patients with a positive depression screening and documented follow-up plan during the measurement year}}{\text{Denominator: Total number of active patients at least 12 years of age during the measurement year.}}
 \end{array}$$

#### Measure Rationale

Screening for depression is an important first step in increasing behavioral health utilization, which is low for SFHP members. In addition, depression has a large effect on health care costs and on productivity. It is estimated that monthly depression-related worker productivity losses had human capital costs of nearly \$2 billion while adults with depression or depressive symptoms have significantly higher health care costs, even after adjusting for chronic medical conditions (Katon et al., 2003). Inclusion of this measure supports early detection with potential for cost savings from treatments associated to health complications from depression. Both PRIME and HEDIS have similar measures.

#### Measure Source

Inclusion of this measure and PIP benchmark determination is supported by alignment with external healthcare measurement entities, including Centers for Medicare and Medicaid Services (CMS).

#### Definitions

Follow-up for a positive depression screening must include one (1) or more of the following:

- Additional evaluation for depression
- Suicide risk assessment
- Referral to a practitioner who is qualified to diagnose and treat depression
- Pharmacological interventions
- Other interventions or follow-up for the diagnosis or treatment of depression

Examples of a follow-up plan include but are not limited to:

- Additional evaluation or assessment for depression such as psychiatric interview, psychiatric evaluation, or assessment for bipolar disorder
- Completion of any Suicide Risk Assessment such as Beck Depression Inventory or Beck Hopelessness Scale
- Referral to a practitioner or program for further evaluation for depression, for example, referral to a psychiatrist, psychologist, social worker, mental health counselor, or other

mental health service such as family or group therapy, support group, depression management program, or other service for treatment of depression

- Other interventions designed to treat depression such as psychotherapy, pharmacological interventions, or additional treatment options
- Pharmacologic treatment for depression is often indicated during pregnancy and/or lactation. Review and discussion of the risks of untreated versus treated depression is advised. Consideration of each patient’s prior disease and treatment history, along with the risk profiles for individual pharmacologic agents, is important when selecting pharmacologic therapy with the greatest likelihood of treatment effect.

The documented follow-up plan must be related to positive depression screening, for example: “Patient referred for psychiatric evaluation due to positive depression screening.”

**Data Source**

- Self-reported by participant.

**Resources**

- See PIP website for resources including a list of common and vetted depression screening tools for both adolescents and adults.

**Deliverables and Due Dates**

<b>Deliverable</b>	<b>Due Dates</b>	<b>PIP Network Threshold</b>	<b>Relative Improvement</b>	<b>Quarterly Scoring</b>
Self-report the numerator and denominator as noted in the Measure Description, via the quantitative template.	<ul style="list-style-type: none"> <li>• <b>Quarter 1</b></li> <li>• <b>Quarter 2</b></li> <li>• <b>Quarter 3</b></li> <li>• <b>Quarter 4</b></li> </ul>	75 <sup>th</sup> Percentile 66.33%	10% or more	1.0 point
		60 <sup>th</sup> Percentile 57.27%	5-9%	0.5 points

## SI 2: Follow-Up Visit After Hospital Discharge

### 2021 - 2022 Practice Improvement Program Measure Specification

#### **ALL PARTICIPANTS**

#### **Changes from 2020**

No changes.

#### **Measure Description**

Participants will receive points for increasing the rate of follow-up office, home, or telephonic visits within 7 calendar days of hospital discharge from an in-network, contracted hospital. This is the hospital that members assigned to your organization through SFHP are expected to receive hospital services. For questions on this, please contact the PIP team.” Points will be awarded for meeting thresholds (see scoring section below).

**Quarterly Office Visit Follow-Up After Hospital Discharge Rate**

=

**Numerator:** Total number of discharges in the denominator with an eligible follow-up visit 1-7 calendar days post discharge

---

**Denominator:** Total number of inpatient discharges during the quarter

#### **Measure Rationale**

Timely follow-up after hospital discharge has been shown to decrease mortality (Fidahusseini et. al., *Risk Management Healthcare Policy*, 2014) and increase patients’ access of supportive services, such as rehabilitation providers and behavioral health care (Sommers and Cunningham, *National Institute for Health Care Reform Brief No. 6*, 2011). In addition, timely follow-up after hospital discharge can reduce unplanned readmissions and the associated health care costs (Boutwell, et al., 2009). All of the new models of care involve multiple steps that occur both pre- and post-discharge, and all involve multi-disciplinary health care teams. They differ in how and when they use various care team members, as well as in the emphasis placed on certain steps. However, all the models share the following core attributes: an accountable leader or manager, teamwork, medication reconciliation and clinical management of medications, patient and caregiver education, counseling and engagement, and follow-up. Medication management has been highlighted at the core of advanced discharge planning and transitional care (Improving Medical Adherence and Reducing Readmissions, NEHI, Oct 2012).

#### **Measure Source**

Inclusion of this measure and PIP benchmark determination was informed by SFHP in conjunction with the PIP advisory committee.

#### **Definitions**

- An eligible follow-up visit is any outpatient office, home, or telephonic visit that meets all of the following criteria:
  - With an MD, NP, PA, RN, behavioral health provider, or pharmacist.
    - Eligible follow-up visits may also be performed by other staff operating under a standardized procedure with escalation instructions to a provider type noted

above when necessary. To use this option, please provide SFHP with the standardized procedure prior to submission.

- Occurs within 7 calendar days of the discharge
- Includes, at minimum, medication reconciliation and assessment of access to supportive services

**Exclusions**

- Discharges from a psychiatric or maternity unit are excluded.
- Participants with fewer than 30 discharges during April-June 2021 as determined by SFHP are exempt from this measure for the 2021-22 program year.

**Data Source**

- Self-reported by participant.

**Deliverables and Scoring**

<b>Deliverable</b>	<b>Due Date</b>	<b>Threshold</b>	<b>Scoring</b>
Submit quarterly numerator and denominator as noted above via quantitative data template.	<ul style="list-style-type: none"> <li>• <b>Quarter 1</b></li> <li>• <b>Quarter 2</b></li> </ul>	50%	1.0 point
	<ul style="list-style-type: none"> <li>• <b>Quarter 3</b></li> <li>• <b>Quarter 4</b></li> </ul>	40%	0.5 point

## SI 3: Opioid Safety

### 2021-2022 Practice Improvement Program Measure Specification

**Part A: COMMUNITY CLINIC, CLINIC-BASED RBO, & ACADEMIC MEDICAL CENTER ONLY**

**Part B: ALL PARTICIPANTS**

#### Changes from 2020

No changes.

#### Measure Description

**Part A:** Participants will receive points based on the percentage of opioid registry patients who meet the opioid safety requirements:

<p><b>Quarterly Opioid Safety Rate</b></p>	=	<p><b>Numerator:</b> Total number of opioid registry patients who meet the opioid safety requirements: <i>all</i> of the following must be documented in the last 12 months:</p> <ul style="list-style-type: none"> <li>• one drug urine screen (does not have to be random)</li> <li>• a signed opioid treatment agreement</li> <li>• CURES report reviewed</li> </ul> <hr/> <p><b>Denominator:</b> Total number of patients in Opioid Registry on the last day of the Quarter</p>
--	---	---

Participants may choose to report on just their SFHP members, or their entire patient population. For the data to be comparable, this choice must remain consistent from quarter to quarter.

**Part B:** Participants submit a list of the five SFHP members reviewed by the Controlled Substance Review Committee during the months of the quarter via secure email to [PainManagement@sfhp.org](mailto:PainManagement@sfhp.org). Any member with opioid safety risk may be reviewed. Include brief documentation of committee recommendations and attestation that CURES report reviewed. CURES must be run no more than one month prior to review.

#### Measure Rationale

Information from the 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain (<https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm>) indicates that opioid prescriptions have quadrupled and over 165,000 people have died from prescription opioids since 1999. In addition, it is estimated that the financial toll of opioid overuse, including direct health care costs, lost productivity, and costs to the criminal justice system totals \$78.5 billion. SFHP has seen a decrease in the prevalence of members who have received opiate prescriptions from 2013 through 2016; this trend is likely due to a number of factors, including increased awareness and local, state and federal efforts to reduce opiate prescribing. We consider this PIP measure as an important contributor to the positive trends we have seen. Thank you, PIP participants! However, opioid prescribing still carries great risks. This measure intends to mitigate those risks by incentivizing best practices through panel management and interdisciplinary collaboration on treatment plans for patients receiving opioid prescriptions. By supporting best practices for opioid prescribing, there is potential to reduce costs to the health care system associated to the opioid epidemic.

**Measure Source**

Inclusion of this measure and PIP benchmark determination was informed by SFHP in conjunction with the PIP advisory committee.

**Data Source**

- Self-reported by participant.

**Exemptions & Exclusions**

- Participants with < 15 SFHP/HSF members meeting the chronic opioid treatment criteria (as outlined in the definitions section) are exempt from Part A and Part B.
- Patients with a diagnosis of cancer, who have moved, changed clinics, were lost to follow up, or are deceased are excluded.
- Patients who are physiologically unable to produce urine are excluded from the random drug urine screen requirement in Part A’s numerator. They are not, however, excluded from the other opioid safety requirements (a signed pain management agreement and CURES report review).

**Deliverables and Due Dates**

Deliverable	Due Date	Thresholds	Quarterly Scoring
<b>Deliverable A:</b> Self-report the numerator and denominator as noted in the Measure Description, via quantitative template.	• <b>Quarter 1</b>	≥ 60%	<b>0.5 point</b>
	• <b>Quarter 2</b>	50-59%	<b>0.25 point</b>
	• <b>Quarter 3</b> • <b>Quarter 4</b>	49% or less	<b>0 point</b>
<b>Deliverable B:</b> Submit template with the names of 5 SFHP members with opioid safety risk reviewed <u>during the quarter</u> by the Controlled Substance Review Committee. Include brief documentation of committee recommendations and attestation that CURES report reviewed. CURES must be run no more than one month prior to review. Members with concurrent opioid and benzodiazepine prescriptions will be prioritized for review, based on a member list provided by SFHP <sup>1</sup> .	• <b>Quarter 1</b> • <b>Quarter 2</b> • <b>Quarter 3</b> • <b>Quarter 4</b>		<b>0.1 point/member, up to 0.5 point</b> , will be awarded for submitting (via secure email) <sup>2</sup> the completed template listing the 5 SFHP members reviewed by the Controlled Substance Review Committee to <a href="mailto:PainManagement@sfhp.org">PainManagement@sfhp.org</a> .

<sup>1</sup> SFHP will provide member lists at least one month before the start of each quarter (June, September, December, March)

<sup>2</sup> If participants do not have the ability to send secure email, please email [PainManagement@sfhp.org](mailto:PainManagement@sfhp.org) to set-up an alternative arrangement.



## Definitions

**Chronic Opioid Treatment for Non-Cancer Pain:** Patients who are prescribed 20mg or more morphine equivalents per day for at least 72 days in the last 3 months for non-cancer pain.

**Opioid Safety Risk:** As recent evidence and news reports have indicated, opioid prescriptions present inherent risk. With that said, there are some situations that present greater risk. Examples are provided below to assist participants in identifying instances where greater attention may be beneficial. Please note that these situations should not preclude patients from being eligible for opioid prescriptions; rather, they are provided to help participants organize and refine their efforts.

Per the CDC's 2016 Guidelines, here are some examples of situations presenting greater opioid safety risk:

- Patients receiving concurrent opioid (of any dose/length) any and benzodiazepine prescriptions
- Patients receiving Methadone prescriptions for the treatment of chronic pain
- Patients receiving Methadone for treatment as part of Opiate Treatment Program
- Patients over the age of 65 and receiving any opioid prescription (of any dose/length)
- Patients with renal or hepatic insufficiency receiving any opioid prescription (of any dose/length)
- Patients with current or a history (personal or family) of substance abuse and/or any prior non-fatal overdose requesting and/or receiving any opioid prescription (of any dose/length)
- Patients with mental health diagnoses receiving any opioid (of any dose/length)

**Opioid Registry:** As one of the most effective panel management tools, SFHP highly encourages the use of a registry to track patients receiving chronic opioids. It is optional to also include patients presenting opioid safety risk. A registry is a list of patients that meet a certain criteria, usually a diagnosis. Registries provide a tracking system with which to manage a group of patients, helping to ensure quality standards are met. SFHP can provide a list of patients that meet the above criteria on a quarterly basis if a participant is unable to develop a registry or otherwise desires this information. Please request this from the program administrators.

**Opioid Safety Requirements:** Each of the following is documented in the last 12 months:

- One drug urine screen performed (UTOX) (does not have to be random),
- A signed opioid treatment agreement on file,
- CURES report reviewed

**Controlled Substance Review Committee:** A committee providing independent review of records for patients on chronic opioid treatment or those that present opioid safety risk. Reasons reviewed can include patients with high doses, new patients, patients with suspicious urine drug screens, or patients with other concerning behaviors. Controlled Substance Review Committees help providers stay accountable to clinic practice guidelines, and support the clinic's ability to practice consistently and follow best practices. Ideally, this committee is multi-disciplinary in order to allow for informed recommendations on continuing therapy, adding non-opiate therapy, referring to substance use or behavioral health, and weaning opiate therapy. At a minimum, the committee must contain two prescribers. Small clinics may implement medical director review if staffing is not sufficient for a committee.

**CURES Department of Justice Report:** Online state database containing information for all controlled substance prescriptions filled by every patient in California. Includes all payer sources including cash. Registration requires online sign-up the link below, then having a notary public certify the provider's signature and medical license. SFHP will provide a notary public to facilitate provider registration upon request. Reviewing the CURES report at least annually, and for all new patients, allows prescribers to better identify patients who are receiving medications from multiple sources and are at risk for addiction and diversion. <https://pmp.doj.ca.gov/pdmp/index.do>

## ~~SI 4: Providers Open to New Members~~

### 2021 - 2022 Practice Improvement Program Measure Specification

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

#### **IPAs ONLY**

#### **Changes from 2020**

No changes.

#### **Measure Description**

Participants will receive points for increasing the percent of Primary Care Providers (PCPs) that accept new members.

$$\begin{array}{l}
 \text{Quarterly} \\
 \text{Rate of} \\
 \text{Providers} \\
 \text{Open to} \\
 \text{New} \\
 \text{Members}
 \end{array}
 = \frac{\text{Numerator: PCPs in the denominator open to new members and to auto-assigned members. Auto-assigned members are new members who do not choose a Primary Care Provider on enrollment with SFHP.}}{\text{Denominator: Total number of PCPs affiliated with SFHP as of the last week of the Quarter.}}$$

#### **Measure Rationale**

Provider accessibility is a key requirement for primary health care (Access to Health Services, 2013). Since Medi-Cal expansion in 2014, it has become increasingly important that the influx of new members have adequate choice and access to providers. The purpose of this measure is to increase the percentage of PCPs accepting new members. This measure can help curb healthcare costs by increasing opportunity for new members to establish strong preventive health practices.

#### **Measure Source**

Inclusion of this measure and PIP benchmark determination was informed by SFHP in conjunction with the PIP advisory committee.

#### **Data Source**

Provider data submitted to SFHP by medical groups.

#### **Deliverables and Due Dates**

Deliverable	Due Date	Relative Improvement	Threshold	Quarterly Scoring
		≥ 15%	80% or more	2.0 points

<b>No deliverables required for this measure.</b>	<ul style="list-style-type: none"> <li>• <b>Quarter 1</b></li> <li>• <b>Quarter 2</b></li> <li>• <b>Quarter 3</b></li> <li>• <b>Quarter 4</b></li> </ul>	10-14%	70-79%	<b>1.5 points</b>
		5-9%	60-69%	<b>1.0 point</b>

# SI 5: Percent of Members with a Primary Care Visit

2021 - 2022 Practice Improvement Program Measure Specification

**ALL PARTICIPANTS**

**Changes from 2020**

No changes.

**Measure Description**

This measure uses SFHP claims/encounter data to determine the percentage of SFHP Medi-Cal members assigned to your organization with at least one primary care visit in the last year. Participants will earn points for improvement of the primary care visit rate.

$$\begin{array}{l}
 \text{Quarterly} \\
 \text{Primary} \\
 \text{Care Visit} \\
 \text{Rate}
 \end{array}
 =
 \frac{\text{Numerator: Number of SFHP members in the denominator population with at least one PCP visit in the last year}}{\text{Denominator: Total number of continuously enrolled SFHP Medi-Cal members assigned to your organization during the quarter.}}$$

**Measure Rationale**

Establishing routine PCP visits can identify and treat health conditions early, potentially reducing health care costs from treatment due to health complications. SFHP has found overall primary care utilization is low among its members and disparities exist between medical groups. There is room for improvement across the network. This measure supports appropriate outreach to members who would most benefit from routine primary care visits.

Outreach may be conducted in various ways. SFHP recommends participants consider member age and visit history when identifying the appropriate outreach population. Upon request SFHP can provide your organization with a list of assigned members who had an ED visit but no primary care visit in 2021-22.

**Measure Source**

Inclusion of this measure is supported by alignment with the SFHP fiscal year 17/18 organizational goal.

**Definitions**

- Primary Care Provider (PCP): Rendering provider identified as a PCP according to SFHP provider data.
- PCP Visit: A PCP visit occurs when a member receives primary care services. Beyond a member’s assigned PCP, this includes visits by other PCPs and urgent care providers.

**Data Source**

- SFHP claims/encounter data.

**Deliverable Schedule**

SFHP will send participants PCP visit rate.

<b>Deliverable</b>	<b>Due Date</b>	<b>Scoring</b>
<b>Deliverable A:</b> Receive PCP visit rate. No submission required.	SFHP to provide in: Quarter 1, Quarter 2, Quarter 3, Quarter 4	<i>To be scored Q4.</i>  <b>1.0 points</b> for achieving 5% or more absolute improvement over baseline* or achieving SFHP average PCP visit rate.  <b>0.5 points</b> for achieving 3% absolute improvement over baseline.*  <b>0.25 points</b> for achieving 1% absolute improvement over baseline.*
<b>Deliverable B:</b> Submit improvement plan template (for participants not meeting SFHP average PC visit rate in Q1 2021)	Quarter 2	<b>1.0 points</b>

## ~~SI 6: Palliative Care~~

### 2021 - 2022 Practice Improvement Program Measure Specification

\*Removed from 2021-22 program due to COVID-19. Measure to return in 2022-23.

#### **ALL PARTICIPANTS**

#### **Changes from 2020**

- No changes.

#### **Measure Description**

Participants will receive points for identifying the palliative care resources available within their network and building capacity to identify members who may be eligible for referral to palliative care services.

Part A (All Participants): Identify members who may be eligible for referral to palliative care services by completing the following:

- Identify patients who are potentially eligible for palliative care by using an SFHP list of members who are potentially eligible for palliative care, or creating your own list of potentially eligible patients.
- For potentially eligible members:
  - Complete chart review to determine eligibility for referral to palliative care services as defined by DHCS' minimum eligibility criteria (see Appendix D).
  - For patients found eligible, make appropriate referrals to care
- Attestation by medical director (or equivalent) verifying chart review of members eligible for palliative care and appropriate referrals were made.

#### **Measure Rationale**

Palliative care is specialized medical care for people with terminal diagnoses or serious illness, focused on providing relief from the symptoms and stress of serious illness and improving quality of life for both patients and families. For SFHP members close to end-of-life, palliative care can deliver care that is important to patients and often lacking from traditional medical services. Palliative care services help assess patients' and families' goals of care and match treatments to goals. Subsequently, potential cost savings may be associated to a reduction of mismatch between medical treatments and patient preferences.

#### **Measure Source**

Inclusion of this measure supports the new palliative care benefit for SFHP members and is supported by alignment with external healthcare entities, including the Department of Managed Health Care regulations.

#### **Data Source**

- Self-reported by participant.

- Upon request, SFHP will provide participant with a list of their assigned SFHP members diagnosed with COPD or CHF.

**Resources**

See PIP website for resources for COPD and CHF diagnosis codes and DHCS Palliative Care Eligibility Criteria.

**Exclusions**

- Participants with fewer than 30 SFHP members diagnosed with COPD and CHF are exempt from this measure for the 2021 - 2022 program year, as determined by SFHP’s palliative care member roster run July 2021.

**Deliverable Schedule**

<b>Deliverable</b>	<b>Due Date</b>	<b>Scoring</b>
<b>Deliverable A:</b> Submit attestation signed by a medical director (or equivalent), verifying that chart review was performed for patients with COPD or CHF potentially eligible for palliative care and appropriate referrals were made.	Quarter 4	4.0 points

**Definitions**

If COPD and CHF were chosen as the focus in 2020, then one of the two other groups below must be the focus in 2021-22:

- **Advanced Cancer:** Must meet (a) and (b)
  - a. The member has a stage III or IV solid organ cancer, lymphoma, or leukemia
  - b. The member has a Karnofsky Performance Scale score less than or equal to 70 or has failure of two lines of standard of care therapy (chemotherapy or radiation therapy).
    - **Liver Disease:** Must meet (a) and (b) combined or (c) alone
      - a. The member has evidence of irreversible liver damage, serum albumin less than 3.0, and international normalized ratio greater than 1.3
      - b. The member has ascites, subacute bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, or recurrent esophageal varices
      - c. The member has evidence of irreversible liver damage and has a Model for End Stage Liver Disease (MELD) score greater than 19.



## Section VIII: Appendix

### Appendix A: DQ 1 Sample Report

SFHP-produced, participant to update

Clinic A Provider Roster

**EXAMPLE**

First and Last Name (legal with preferred in parenthesis)	Medical Degree	Type of Practitioner (PCP or Specialist)	Primary Specialty	Secondary Specialties (if applicable)	Language(s)	License Number	Email Address	Name of MD/DO Supervisor (For NPs, PAs, CNMs only)	Site Name	Language(s) Spoken At Site	Hours & Days Site is Open	Date listed with SFHP	Date terminated/left the organization (if applicable)	Open to new members (Y/N) (For non-SFHN PCPs only)	Open to Auto Assignment (Y/N) (For non-SFHN PCPs only)
ARROYO, ABIGAIL (ABBY)	MD	PCP	PEDIATRICS	ADOLESCENT MEDICINE	ARABIC, ENGLISH, SPANISH	XXXXXXX	<a href="mailto:a.arroyo@clinica.org">a.arroyo@clinica.org</a>		CLINIC A	ARABIC, CANTONESE, ENGLISH, MANDARIN, PORTUGEUSE, RUSSIAN, SPANISH	M-F 8AM-5PM, SAT 9AM-3PM	7/8/2011		Y	Y
OLIVERA, BLAKE	NP	SPECIALIST	PSYCHIATRY	PEDIATRIC MEDICINE	ENGLISH, PORTUGEUSE	XXXXXXX	<a href="mailto:b.olivera@clinica.org">b.olivera@clinica.org</a>	ABIGAIL ARROYO	CLINIC A	ARABIC, CANTONESE, ENGLISH, MANDARIN, PORTUGEUSE, RUSSIAN, SPANISH	M-F 8AM-5PM, SAT 9AM-3PM	5/13/2009			

## Appendix B: Measure Set by Participant-Type Grid

NOTE: An “X” indicates the measure is included in the participant-type’s measure set.

Measure	Community Clinic	Clinic-Based RBO	IPA	Academic Medical Center
<b>Clinical Quality Domain</b>				
CQ01 Diabetes HbA1c Test	X	X	X	X
CQ02 Diabetes HbA1c <8 (Good Control)	X	X	X	X
CQ03 Diabetes Eye Exam	X	X	X	X
CQ04 Routine Cervical Cancer Screening	X	X	X	X
CQ05 Routine Colorectal Cancer Screening	X	X		
CQ06 Breast Cancer Screenings	X	X	X	X
CQ07 Smoking Cessation Intervention Documented	X	X	-	-
CQ08 Controlling High Blood Pressure (Hypertension)	X	X	X	X
CQ09 Adolescent Immunizations	X	X	X	X
CQ10 Childhood Immunizations	X	X	X	X
CQ11 Well Child Visits for Children 3-6 Years of Age	X	X	X	X
CQ12 Chlamydia Screening	X	X	X	X
CQ13 Timely access to Prenatal Care	-	X	X	-
CQ14 Postpartum Care	-	X	X	-
CQ15 Asthma Medication Ratio	-	X	X	-
CQ16 Well Child Visits in the First 15 Months of Life	X	X	X	X
CQ17 Well Child Visits in Children 15-30 Months of Age	X	X	X	X
<b>Data Quality Domain</b>				
DQ1 Provider Roster Updates			X	X
<b>Patient Experience Domain</b>				
PE1 Third Next Available Appointment (TNAA)	X	X	-	-
PE2 Office Visit Cycle Time	X	X	-	X
PE3 Staff Satisfaction Improvement Strategies	X	X	-	X
PE4 Improvement in Patient Experience of Primary Care Access (CG-CAHPS)	X	X	X	X
PE5 Appointment Availability Survey Compliance (Primary Care)	-	-	X	X
PE6 Improvement in Specialty Access (HP-CAHPS)	-	X	X	-
<b>Systems Improvement Domain</b>				
SI1 Depression Screening and Follow-up	X	X	X	X
SI2 Follow-Up Visit After Hospital Discharge	X	X	X	X
SI3 Opioid Safety	X	X		X
SI4 Providers Open to New Members	-	-	X	-
SI5 Percent of Members with a Primary Care Visit	X	X	X	X

S16 Palliative Care	X	X	X	X
---------------------	---	---	---	---

## Appendix C: CG-CAHPS Composite Questions

Composite	Question	Response Options
<b>Access to Care</b>	In the last 6 months, did you contact this provider's office to get an appointment for an illness, injury, or condition that needed care right away?	Yes/No If no, the respondent skips to next question in the composite
	In the last 6 months, when you contacted this provider's office to get an appointment for care you needed right away, how often did you get an appointment as soon as you needed?	Never Sometimes Usually Always
	In the last 6 months, did you make any appointments for a check-up or routine care with this provider?	Yes/No If no, the respondent skips to next question in the composite
	In the last 6 months, when you made an appointment for a check-up or routine care with this provider, how often did you get an appointment as soon as you needed?	Never Sometimes Usually Always
	In the last 6 months, did you contact this provider's office with a medical question during regular office hours?	Yes/No If no, the respondent skips to next question in the composite
	In the last 6 months, when you contacted this provider's office during regular office hours, how often did you get an answer to your medical question that same day?	Never Sometimes Usually Always
	<b>Customer Service (reporting-only)</b>	In the last 6 months, how often were clerks and receptionists at this provider's office as helpful as you thought they should be?
In the last 6 months, how often did clerks and receptionists at this provider's office treat you with courtesy and respect?		Never Sometimes Usually Always
<b>How Well Providers Communicate with Patients (reporting-only)</b>	In the last 6 months, how often did this provider explain things in a way that was easy to understand?	Never Sometimes Usually Always
	In the last 6 months, how often did this provider listen carefully to you?	Never Sometimes Usually Always
	In the last 6 months, how often did this provider show respect for what you had to say?	Never Sometimes Usually Always
	In the last 6 months, how often did this provider spend enough time with you?	Never Sometimes

		Usually Always
--	--	-------------------

## Appendix D: Palliative Care Diagnosis Codes and DHCS Eligibility Criteria

### Diagnosis codes used to identify patients with CHF and COPD (source: Partnership Health Plan)

Class	Diagnosis	ICD9	ICD10
<b>CHF</b>	Cardiomyopathy	425	I50.1 - I50.9
	Heart Failure	428	I11.0, I13.0, I13.2
<b>COPD</b>	Asbestosis	501	J61
	Bronchiectasis	494	J47
	Chronic bronchitis	491	J41, J42,
	COPD	496	J44.0, J44.1, J44.9
	Emphysema	492	J43.1, J43.2, J43.9

### SB 1004 Palliative Care Eligibility Criteria for Patients with CHF or COPD (Source: DHCS APL)

DHCS’ minimum eligibility criteria requires a beneficiary to meet all requirements for the general eligibility criteria and at least one of the four disease-specific eligibility requirements.

#### A. General Eligibility Criteria:

1. The beneficiary is likely to or has started to use the hospital or emergency department as a means to manage his/her advanced disease. This refers to unanticipated decompensation and does not include elective procedures.
2. The beneficiary has an advanced illness, as defined in section B below, with appropriate documentation of continued decline in health status, and is not eligible for or declines hospice enrollment.
3. The beneficiary’s death within a year would not be unexpected based on clinical status.
4. The beneficiary has either received appropriate patient-desired medical therapy or is a beneficiary for whom patient-desired medical therapy is no longer effective. Patient is not in reversible acute decompensation.
5. The beneficiary and, if applicable, the family/patient-designated support person, agrees to:
  - a. Attempt, as medically/clinically appropriate, in-home, residential-based, or outpatient disease management/palliative care instead of first going to the emergency department; and
  - b. Participate in Advance Care Planning discussions.

#### B. Disease-Specific Eligibility Criteria:

1. Congestive Heart Failure (CHF): Must meet (a) and (b)

- a. The beneficiary is hospitalized due to CHF as the primary diagnosis with no further invasive interventions planned OR meets criteria for New York Heart Association (NYHA) heart failure classification III or higher<sup>3</sup>; AND
  - b. The beneficiary has an Ejection Fraction of less than 30 percent for systolic failure OR significant co-morbidities.
2. Chronic Obstructive Pulmonary Disease (COPD): Must meet (a) or (b)
- a. The Beneficiary has a Forced Expiratory Volume (FEV)<sub>1</sub> less than 35 percent of predicted AND a 24-hour oxygen requirement of less than three liters per minute; OR
  - b. The beneficiary has a 24-hour oxygen requirement of greater than or equal to three liters per minute.

If a beneficiary continues to meet the above minimum eligibility criteria, he or she may continue to access both palliative care and curative care until the condition improves, stabilizes, or results in death. Medi-Cal managed health plans (MCPs) should periodically assess the beneficiary for changes in his/her condition or palliative care needs. MCPs may discontinue palliative care that is no longer medically necessary or reasonable.

---

<sup>3</sup> NYHA classifications are available at:  
[http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-HeartFailure\\_UCM\\_306328\\_Article.jsp#.WefN7rpFxxo](http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-HeartFailure_UCM_306328_Article.jsp#.WefN7rpFxxo)

# Appendix E: Templates

SI 3: Deliverable B

**SI 3: Opioid Safety**  
 Due: Quarterly



Number	Member Name	Date of Birth	SFHP ID #	Run Date of CURES Reviewed by Committee (must be within 1 month of review)	Date Reviewed	Reason Reviewed	Brief Recommendations
1							
2							
3							
4							
5							

**Note: If patient is not covered by SFHP or HSF, then do not give name or ID # information in order to be HIPPA compliant. Also please securely email this list to PainManagement@sfhp.org. If unable to send secure email, send an email to that address to initiate secure email exchange.**

**SI 5: Deliverable B (For participants not meeting SFHP average PC visit rate only)**

**SI 5: Percent of Members with a Primary Care Visit**

Quarter 2 Template

(Due: January 31, 2022)

**Improvement Plan**

Please submit an improvement plan detailing the activities that will be implemented to improve the Quarterly Primary Care Visit Rate. (Please add rows as needed.)

Proposed improvement activities	Staff Responsible	Date to be completed
1.		
2.		



